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Significance: Antineoplastic therapies have improved the prognosis of oncology patients 
significantly. 
However, these treatments can bring to a higher incidence of side effects, including 
the worrying cardiovascular toxicity (CTX). 
Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox 
mechanisms playing a key role. Recent data singled out mitochondria as key targets for 
antineoplastic drug-induced CTX; understanding the underlying mechanisms is therefore crucial 
for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. 
Critical Issues: CTX can occur within a few days or many years after treatment. Type I CTX 
is associated with irreversible cardiac cell injury, and is typically caused by anthracyclines 
and traditional chemotherapeutics. Type II CTX is generally caused by novel biologics and 
more targeted drugs, and is associated with reversible myocardial dysfunction. Therefore, patients 
undergoing anti-cancer treatments should be closely monitored, and patients at risk of 
CTX should be identified before beginning treatment to reduce CTX-related morbidity. 
Future Directions: Genetic profiling of clinical risk factors and an integrated approach using 
molecular, imaging, and clinical data may allow the recognition of patients at high-risk of developing 
chemotherapy-related CTX, and may suggest methodologies to limit damage in a 
wider range of patients. The involvement of redox mechanisms in cancer biology and anticancer 
treatments are a very active field of research. Further investigations will be necessary to 
uncover the hallmarks of cancer from a redox perspective and to develop more efficacious 
antineoplastic therapies that also spare the cardiovascular system. 
 
1. Introduction: The clinical problem of antineoplastic drug cardiovascular toxicity 
During the last years, the prognosis of cancer has been greatly enhanced by advancements in 
antitumoral therapeutic protocols; many types of malignancies can now be cured or 
maintained in remission for a long time, allowing patients to live the rest of their lives in 
remission from cancer (22, 132, 173, 267, 392). Unfortunately, antitumoral treatments exert 
some adverse side effects (Table 1). The cardiovascular (CV) system can be negatively 
affected by such therapies, and this is especially true in the so-called long-term cancer 
survivors, since the likelihood that cardiac side effects of antitumoral treatments become the 
main health problem after tumor elimination increases with survival (250, 287, 429, 432). 
The most common CV complications of antineoplastic therapies include vasospastic and 
thromboembolic ischemia, arterial hypertension, dysrhythmia, and left ventricular (LV) 
dysfunction, leading to heart failure (HF) (25, 204, 376, 429, 432). Cardiac dysfunction 
caused by anthracyclines (ANTs) has long been known as the main form of anti-cancer druginduced 
cardiotoxicity (CTX) (91-94), with production of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) being considered main cytotoxic mechanisms (see Section 10 
for details). In the last decades, new biologic anti-cancer drugs, such as intracellular signaling 
inhibitors, are being increasingly used. These molecules may also be cardiotoxic, since they 
block pathways that are major modulators of myocardial function, especially under conditions 
of cardiac stress, such as hypertension or hypertrophy (376), with mechanisms of action that 
often involve redox signaling, too. As an example, drugs that target the human epidermal 
growth factor receptor 2 (HER/ErbB2) and the vascular endothelial growth factor (VEGF), 
exert a considerable adverse effect on myocardial function via different mechanisms, based on the 
role of the proteins inhibited. The toxicity produced by biologic drugs seems to be due to 
mechanisms other than cardiomyocyte disruption, is most often reversible with 
discontinuation of the drugs, and has been classified as type II CTX (93, 94). On the other 
hand, ANTs produce a form of cardiac dysfunction which is typically irreversible, termed 
type I CTX, and which is characterized by evident ultrastructural myocardial abnormalities 
(93, 94). Of note, these two CTX paradigms may overlap. One paradigmatic example is the 
ErbB2 receptor inhibitor trastuzumab, that can cause irreversible LV dysfunction in patients 
previously treated with ANTs (376, 432), with the neuregulin/ErbB2 pathway which seems to 
modulate the increase in ROS caused ANTs (390). 
In this manuscript, we address the main cellular and molecular mechanisms and 
pathophysiologic and clinical characteristics of antineoplastic drug-related CTX, since only a 
comprehensive assessment of this phenomenon can provide important hints to predict, treat, 
and prevent it. Special emphasis is placed on LV dysfunction and HF, in consideration of their 
clinical and social burden (25, 125), with updated insights concerning the role of oxidative 
damage, a mechanism that appears to have a major role in antineoplastic drug-induced CTX 
(412, 432). Whenever appropriate, we divided the various Sections in three categories a) 
adverse effects, b) mechanisms of adverse effects and c) ways to reduce cardiovascular 
toxicity. 
 
2. Anthracyclines (ANTs) 
Among the drugs with greater cardiotoxic potential, ANTs are good representatives of the type I CTX 
paradigm. ANTs are widely used and effective antineoplastic drugs, indicated for the therapy of many 
kinds of cancers including lymphomas, leukemias, and sarcomas, and for both early and advanced 
breast cancer. However, these drugs have been recognized as cardiotoxic since the 1960s (384). 
Adverse effects: ANT-induced CTX can manifest as a sort of cardiomyopathy, referred to as ANT-
induced cardiomyopathy, leading to HF, which limits the usability of the drugs, with important 
consequences for managing malignancies. ANT-related CTX represents a significant clinical burden, 
producing LV dysfunction in up to 9% of cases in a recent large prospective study (35). Mechanisms 
of adverse effects: ANT-related CTX mechanisms are derived from a combination of several cellular 
and molecular alterations leading to myocardial damage and dysfunction (Fig. 1). ANT-induced CTX 
is still not completely understood, though new insights on molecular mechanisms have been 
elucidated in recent years (373, 432, 435). The role of redox stress, resulting from an overproduction 
of ROS/RNS, in ANT-related CTX is undisputed (246, 247, 353, 434), although mechanisms are 
much less clear (see Section 10for further details). ROS and RNS may be either direct or indirect 
inducers of the cardiac injury, but also triggers, byproducts of the injury or end-products arising from 
the injury itself. Inaddition, severity of oxidative/nitrosative stress often does not correspond well 
with the severity of the injury. This is connected to acceptance and explanation of poor efficacy of 
different antioxidants under relevant conditions. Recent data suggest that ANT-induced CTX is also 
strictly related to ANT interaction with topoisomerase 2 (Top2)-β in cardiomyocytes (229). Two 
types of Top2 enzymes are targeted by ANTs: Top2-α and Top2-β. While the former is present in 
rapidly dividing cells, such as cancer cells, and forms the ternary Top2-doxorubicin-DNA cleavage 
complex, inducing cell apoptosis, Top2-β is present in human cardiomyocytes, forming the Top2β-
doxorubicin-DNA complex, which causes DNA doublestrand breaks and transcriptome 
modifications, also leading to cell apoptosis (434). A seminal paper confirmed the crucial role of the 
Top2-β gene in an animal model, demonstrating that cardiomyocyte-specific deletion of the Top2-β 
gene is protective against ANT-induced damage (434). The DNA break caused by doxorubicin 
binding to Top2-β can therefore stimulate the DNA injury response. Consequently, the tumor 
suppressor protein p53, a fundamental enzyme for activating DNA repair proteins, can be induced. 
Unfortunately, p53 can also cause defective mitochondria biogenesis and metabolic failure by 
suppressing genes involved in organelle biogenesis, such as peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1α), and alteration of oxidative phosphorylation 
(OXPHOS) (434). Intriguingly, the metabolic perturbations induced by doxorubicin-activated p53 
are responsible for altered autophagy, a process necessary for the normal recycling of dysfunctional 
mitochondria. Consequently, doxorubicin-damaged mitochondria accumulate in the cardiomyocytes, 
resulting in enhanced ROS/RNS generation and ultimately cell death. Recent observations in p53-
null mice found a smaller impairment in cardiac functional reserve after ANT treatment, supporting 
this hypothesis (157). Interestingly, in these mice, mitochondrial and LV function were maintained 
with increasing age, suggesting that p53-mediated inhibition of autophagy may play a role in all forms 
of cardiac dysfunction, not just doxorubicin-induced cardiomyopathy (157). Apart from p53, 
doxorubicin may also induce the mitogen-activated protein kinase (MAPK) pathway via ROS- and 
Ca2+-dependent mechanisms (437). Importantly, extracellular signalregulated kinases (ERKs), 
members of the MAPK family, may protect myocytes from apoptosis, while p38 MAPK induces 
death of cardiomyocytes (437). More studies are needed to elucidate the role of such kinases and of 
other less-characterized signaling pathways in ANTinduced cardiotoxicity. However, these data 
confirm that oxidative reactions, at the basis of ANT-induced LV dysfunction, are involved in most 
types of HF. Therefore, timely innovative pharmacological strategies that interfere with specific 
molecules involved in heart dysfunction (e.g. p53) may represent a potential common approach in 
limiting HF occurrence (250, 341). ANT-alcohol metabolites also play a pivotal role in inducing 
cellular injury and CTX via iron-dependent and -independent mechanisms. In fact, these metabolites 
disrupt iron and calcium homeostasis and, ultimately, lead to intracellular Ca2+ overload. Calcium 
overload has also been related to increased calpain proteolytic activity, which leads to cellular 
disarray and sarcomere disruption, resulting in sarcopenia (220). In addition, the interaction of ANTs 
with critical signaling pathways and with the activity of transcription factors may also explain 
sarcopenia, which derives from the limitation of sarcomere protein synthesis (165). Mitochondrial 
activity has a central role in ANT-induced CTX (257, 258). The presence of doxorubicin in the 
mitochondrion, due to a high affinity for the mitochondrial phospholipid cardiolipin, negatively 
affects its function, stimulating ROS/RNS production, inhibiting oxidative phosphorylation, and 
causing mitochondrial DNA damage (300), with a consequent progressive reduction of energy 
production leading to cell dysfunction (210). ANTs also appear to be responsible for mitochondrial 
calcium accumulation (300), leading to mitochondrial membrane injury. The mitochondrial pathway 
is an additional mechanism responsible for cellular intrinsic apoptosis. This involves elements of the 
outer mitochondrial membrane (OMM), including Bax and Bak, and activates cytochrome C and 
caspase, among others (257). 
Some researchers have hypothesized that the loss of iron homeostasis and the Ca2+ overload caused 
by ANT alcohol metabolites, impairing cardiomyocyte energy and redox balance, could be sufficient 
to induce significant myocardial dysfunction, and that in addition, cardiac injury could be increased 
by an apoptotic loss of cardiomyocytes triggered by ROS and Fe2+ (257, 258). ANTs can also affect 
cardiac progenitor cells, hampering the regeneration capabilities of cardiac tissues following 
myocardial damage (158, 289). The controversy on the role of cardiac stem cells is discussed in 
Section 12. Finally, it should be noted that several factors can favor ANT-induced CTX, and this may 
explain the individual variability in CTX occurrence (246, 247) (Fig. 2). The so-called multiplehit 
hypothesis considers a late onset of CTX due to pharmacological and non-pharmacological 
subsequent injury. Therefore, strategies favoring cardiac adaptation to various stressors are crucial 
following ANT therapy (244). Of course, a better understanding of the molecular mechanisms of 
ANT-related CTX is essential in order to choose the best strategies to prevent and treat CTX (33, 231, 
232, 345, 408). Ways to reduce cardiovascular toxicity: Several approaches have been proposed to 
reduce ANT cardiotoxicity, including ACE-inhibitors, β blockers, Doxrazoxane, PDE-5 inhibitors, 
Ranolazine and Statins, as well as nutritional supplementation and exercise training. The way the 
various approaches may reduce cardiovascular toxicity by ANT is treated in Sections 10 and 11. 
 
3. ErbB2 inhibitors 
ErbB2 (also called HER2) is a member of the human epidermal growth factor receptor family, which 
also includes ErbB1, ErbB3, and ErbB4. When bound by their ligands, these transmembrane receptors 
homodimerize or heterodimerize and are trans-phosphorylized, thus initiating several cellular 
responses. Until now, no specific ligand for ErbB2 has been identified, and the protein is believed to 
act as a dimerization partner of the other ErbBs (107). Importantly, ErbB2 is overexpressed in 
approximately 30% of breast cancer cases, and can then interact spontaneously with other ErbBs 
independently from ligand stimulation, thus triggering signaling pathways that stimulate tumor 
growth and survival (361). Adverse effects: Trastuzumab is a humanized monoclonal antibody that 
binds the extracellular domain IV of HER/ErbB2 (107, 377). It is the prototypical anti-ErbB2 agent, 
and the first developed and most widely used type II cardiotoxic drug. Trastuzumab is particularly 
useful in treating ErbB2+ breast and gastric cancers. Unfortunately, it can also cause CTX in a 
substantial number of patients, peaking at 28% with concomitant administration of trastuzumab and 
ANTs (262, 362, 377). Indeed, as said, ANTs are responsible for type I CTX with permanent cardiac 
damage. Therefore, reduced left ventricle ejection fraction (LVEF) results from the association of 
trastuzumab and doxorubicin: Trastuzumab enhances or even induces doxorubicin toxicity. Once 
anti-ErbB2 agents block the protective mechanisms of ErbB2, the oxidative damage induced by 
doxorubicin increases (91). This co-administration is now avoided. As a class II cardiac dysfunction 
(93, 94), trastuzumab CTX appears to be elicited by the impairment of contractility rather than the 
loss of cardiomyocytes, and previous chemotherapy seems to be responsible for the troponin release 
observed in sequential treatment (91). Pertuzumab is a more recent anti-HER2 antibody that binds 
the receptor’s domain II. Lapatinib is a different anti-ErbB2 agent, a small-molecule inhibitor of the 
intracellular tyrosine kinase domain of ErbB2. Of note, trastuzumab only disrupts ligand-independent 
ErbB2 signaling, while pertuzumab interferes with the formation of ligand-induced ErbB2 
heterodimers. In contrast, lapatinib inhibits both ligand-induced and ligand-independent ErbB2 
signaling (69). Interestingly, lapatinib seems to be less toxic than trastuzumab. Data regarding the 
toxicity of pertuzumab are more limited (262).  
Mechanisms of adverse effects: Cardiotoxicity of anti-ErbB2 drugs has been attributed to the 
inhibition of fundamental actions of neuregulin 1 in the heart (262, 286). In brief, in response to 
various stimuli, including mechanical strain, adult cardiac microvascular endothelial cells may 
release neuregulin 1 (NRG1, especially the NRG1β isoform) (221). Thus, NRG1 acts on 
cardiomyocytes in a paracrine manner, triggering ErbB4/ErbB4 homodimerization and ErbB4/ErbB2 
heterodimerization to stimulate protective pathways in response to stress (221, 286). The ErbB2 
pathway mediates cell survival and functionality, with recent data focusing on its role in mammalian 
heart regeneration (63), and appears to be stimulated when the heart experiences adverse 
hemodynamics or other stress, such as ANT therapies (Fig. 3) (110). It has been postulated that by 
interfering with the NRG1/ErbB4/ErbB2 axis in the myocardium, anti-ErbB2 agents can cause 
cardiomyocyte damage and eventually HF, and that this is more likely to occur if myocytes are 
concomitantly exposed to other stressors, such as hypertension or doxorubicin (70, 91). Supporting 
such a hypothesis, ErbB2 cardiac KO-mice exhibited dilated cardiomyopathy, with increased 
susceptibility to ANT-induced damage to cardiac myocytes (61, 291). Conversely, overexpression of 
ErbB2 in the heart resulted in lower levels of ROS in mitochondria, with reduced ROS levels and less 
cell death in neonatal myocytes isolated from ErbB2(tg) hearts after doxorubicin treatment, due to 
enhanced levels of glutathione peroxidase 1 (GPx1) protein and GPx activity, with higher levels of 
two known GPx activators, c-Abl and Arg. These data suggest new mechanisms by which ErbB2 
blockers can damage heart structure and function (19). 
These data have led to further studies on NRG1/ErbB4/ErbB2 that have focused away from 
chemotherapy-induced HF to heart disease from any cause, with implications for new therapeutic 
perspectives. For example, in mice subjected to pressure overload, ErbB4 and ErbB2 (both mRNA 
and protein) decreased significantly with the progression of the disease from compensated cardiac 
hypertrophy to overt HF (250, 325). Consistently, ErbB2 and ErbB4 receptor expression and 
activation/phosphorylation were observed to be lower in human failing myocardia, compared with 
organ donors (326). Interestingly, LV unloading by implantation of an LV assist device restored the 
levels of ErbB4 and ErbB2 (326, 400). In an apparent contrast with these results, dogs with pacing-
induced HF showed increased phosphorylation of ErbB4 and ErbB2 (78). Inactivation of the 
intracellular downstream effectors of ErbB4 and ErbB2, ERK1/2 and Akt, was observed, suggesting 
a disabled NRG1/ErbB4/ErbB2 signaling. Actually, NRG1 expression is increased in HF compared 
with control conditions in most studies (78, 250, 326). All in all, these data hint that deranged 
NRG1/ErbB4/ErbB2 activity is involved in the pathophysiology of HF in at least two manners: i) HF 
may derive from the use of anti-ErbB2 drugs, such as trastuzumab; ii) ErbB4/ErbB2 is downregulated 
and/or uncoupled from intracellular signaling despite normal or increased NRG1, possibly leading to 
cardiac decompensation (250). Furthermore, novel observations suggest that levels of 
catecholamines, that usually increase with the occurrence of LV dysfunction and with ANT 
administration (176, 250, 282), can stimulate ErbB2 expression in myocytes, thus making these cells 
particularly susceptible to the effects of trastuzumab, resulting in myocardial toxicity (382). 
Ways to reduce cardiovascular toxicity: The aforementioned experimental results may support the 
use of β blockers in the prevention of trastuzumab CTX (see below) (281), in line with a retrospective 
study that found that continuous use of β blockers was associated with lower risk of new HF events 
in subjects on trastuzumab, ANTs, or both (347). Prevention with β blockers is currently being 
assessed in clinical trials (180, 281, 347, 349) with bisoprolol (MANTICORE 101-Breast) (305), 
NCT01009918 (carvedilol), and NCT01434134/NCT00806390 (metoprolol) to cure or prevent 
trastuzumab-induced LV dysfunction (250, 281). Interestingly, from the recent PRADA (prevention 
of cardiac dysfunction during adjuvant breast cancer therapy) trial, we can infer that blocking only 
β1 with metoprolol may not produce an adequate and sufficient cardioprotection (128), thus 
supporting the use of non-selective β1 and β2 blockers (382). In the clinical setting of trastuzumab-
induced cardiac dysfunction, when trastuzumab is discontinued, normal ErbB2 signaling is restored, 
and the reduced LVEF can increase back to normal levels. Indeed, trastuzumab re-administration 
after discontinuation is considered relatively safe upon LVEF recovery (93, 94). Animal studies have 
demonstrated that NRG1 regulates doxorubicin injury in rat myocytes (390). Owing to the 
aforementioned cardioprotective properties of NRG1 via ErbB4/ErbB2, and as the activity of these 
receptors is altered in HF, the axis neuregulin-ERB is now being intensively investigated in clinical 
trials for HF treatment (111, 112, 221). It has been hypothesized that NRG1 and NRG1 analogs can 
be used as therapeutic agents in HF. Intravenous administration of recombinant human NRG1 and of 
the glial growth factor 2 (GGF2) isoform of NRG1β enhanced heart function and reduced LV 
dimensions in experimental failing heart (111, 112, 218, 227, 250). Since NRG1 exerted positive 
effects in animal models of ischemia-induced HF even when administered after acute myocardial 
infarction, it can be speculated that it is able to produce beneficial reverse remodeling of the damaged 
heart, and does not simply limit cardiac dilation (111, 112, 227). Also, it appears that NRG1 exerts 
an antifibrotic effect, directly inhibiting cardiac fibroblasts, thus preventing fibrosis (111, 112). 
Clinical studies have demonstrated that recombinant human NRG1 is well-tolerated by patients, and 
ameliorates cardiac dimensions and LVEF until up to 3 months after treatment (116, 169). 
Nevertheless, NRG1 may be a growth factor for tumor cells, particularly when administered 
systemically. Hopefully, additional experimental and clinical studies can assess this fundamental 
safety concern, producing novel data concerning the effects of NRG1 in HF (221, 250). 
 
4. Vascular endothelial growth factor (VEGF) inhibitors and multi-targeted kinase inhibitors 
Adverse events: Anti-angiogenic drugs disrupt the VEGF signaling cascade (Fig. 4) and may induce 
type II CTX (Fig 5). VEGF is a modulator of myocardial function and growth, while at the same time 
modulating the integrity and expansion of the coronary and systemic blood vessels (43, 44, 62, 88, 
103, 104, 107, 240, 392). VEGF antagonists may therefore produce different forms of CTX, mainly 
hypertension, thromboembolism, LV dysfunction, and HF (126, 344, 421). 
In particular, bevacizumab, sorafenib, and sunitinib are now widely used for the treatment of different 
cancers. More recently introduced TKIs can also induce CTX. Regorafenib is a multi-target TKI 
whose targets include VEGF receptor (VEGFR) 1-3, endothelial-specific receptor tyrosine kinase 
(trk2), PDGFR, fibroblast growth factor receptor (FGFR), cKIT, RET, and rapidly accelerated 
fibrosarcoma (RAF) kinase. Regorafenib is used in the treatment of colorectal tumors and 
gastrointestinal tumors (28). It may be responsible for arterial hypertension; less frequently, it can 
produce cardiac ischemia and myocardial infarction (30). Pazopanib and axitinib, used in the 
treatment of metastatic renal tumors, are also associated with a high rate of arterial hypertension. 
Pazopanib is an orally administered multi-targeted TKI, targeting VEGFR 1-3, PDGFA and PDGFB 
receptors, and c-KIT. In a recent study, the frequency of pazopanib-associated hypertension varied 
between 36% and 46% (268). Axitinib is a third-generation VEGFR inhibitor used in metastatic renal 
cancer after failure of previous treatments, and is very selective. In a study comparing axitinib and 
sorafenib, the frequency of hypertension was 29% for sorafenib and 40% for axitinib (162). New anti-
angiogenic drugs not yet approved for clinical use are vatalanib and nintedanib. Preliminary evidence 
indicates a potential risk of arterial hypertension and congestive HF and, for vatalanib, of pulmonary 
embolism, although more rarely (318, 407). Mechanisms of adverse effects: The myocardium requires 
appropriate perfusion to function properly (43, 44, 62, 88, 103, 104, 107, 240, 392), and depends on 
HIF-1 and VEGF pathways, similarly to tumors. Of note, inhibition of HIF-1 by p53 may produce 
HF during chronic pressure overload (336). Moreover, conditional expression of a VEGF scavenger 
may cause myocardial hibernation and microvessel rarefaction, which can be reversed by suppressing 
the expression of the scavenger, even months after its induction (244, 417). Such findings show that 
the myocardium is very sensitive to anti-angiogenic treatments, especially with hypertension-related 
pressure overload. The antibody bevacizumab binds circulating VEGF-A, which triggers signaling in 
endothelial cells, and is used as a therapy for advanced lung, breast, and colon/rectum cancers (160, 
334). It has been observed that bevacizumab can induce cardiac dysfunction in 1% of chemotherapy-
naïve patients and 3% of patients with previous chemotherapy (256). Sunitinib and sorafenib are 
small-molecule tyrosine kinase inhibitors (TKIs), and are approved for treating metastatic renal 
cancer and imatinib-resistant gastrointestinal stromal tumors (GISTs) (45, 126). Importantly, they are 
not highly selective, and can inhibit kinases other than VEGF (43). In particular, sunitinib interferes 
with more than 30 other tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) 
alpha and beta, the REarranged during transfection (RET) proto-oncogene, FMS-related tyrosine 
kinase 3 (FLT3), c-Kit, and colonystimulating factor 1 receptor (CSF1R) (43, 107, 135, 230). This 
explains why sunitinib is considered more cardiotoxic than other anti-angiogenic drugs, with an 
incidence of LV dysfunction in up to 28% of patients (51, 187, 269, 387) (Fig. 5). Indeed, all these 
kinases play a role in the maintenance of CV function (9, 168, 217, 228). The high CTX of sunitinib 
is also due to interference with off-target kinases, such as ribosomal S6 kinase (RSK), with 
consequent activation of the intrinsic apoptotic pathway, and 5′ AMP-activated protein kinase 
(AMPK, involved in the response to energy stress), with exacerbation of ATP depletion (107, 186). 
Interestingly, Hasinoff et al. (135) confirmed the inhibition of AMPK in isolated cardiomyocytes, but 
also suggested this is likely not essential for the development sunitinib cardiotoxicity. Creatine kinase 
(CK) may be also involved in the modulation of sunitinib contractile actions (393). A study (51) in 
mice treated with sunitinib also showed a prolonged opening of the non-selective mitochondrial 
permeability transition pore (mPTP) and a significant mitochondrial swelling with deformation of the 
normal mitochondrial architecture in myocytes from heart subjected to pressure overload. Other 
studies (422) showed that sunitinib likely does not induce significant impairment of oxidative 
phosphorylation, thus the impact of sunitinib on energy metabolism is still controversial, with the 
incidence of sunitinib-induced myocardial dysfunction being perhaps lower than initially suggested. 
Additionally, a 2013 manuscript (46) pointed attention from cardiomyocytes to microvascular 
dysfunction in the heart and pericyte damage as another important mechanism of cardiotoxicity 
induced by sunitinib. Sorafenib appears to inhibit at least 15 kinases, including the VEGF receptor, 
PDGFR, Raf-1/B-Raf, FLT3, and c-Kit (43, 107, 392). The incidence of sorafenib-induced CTX is 
not yet fully characterized. In two meta-analyses that included almost 7,000 patients treated with 
sunitinib and 900 patients treated with sorafenib, rates of 4.1% for sunitinib-induced HF and 1% for 
sorafenib-associated cardiac dysfunction were shown (77, 321), but most of these observations were 
derived from retrospective analyses; only a few trials have assessed LV dysfunction prospectively. 
The work of Schmidinger and collaborators (344) showed that three in 14 patients who were 
administered sorafenib and had cardiac events exhibited abnormal LVEF. 
Recently, Feng and coworkers (98) observed that the axis between the brain-derived neurotrophic 
factor (BDNF) and a tyrosine kinase receptor (TrkB) is a key player in the regulation of myocardial 
excitation-contraction coupling, independently and in parallel to G protein-coupled receptor (GPCR) 
signaling. These data further support the concept that tyrosine kinase blockade with antineoplastic 
treatments can interfere with fundamental signaling, thus impairing cardiac mechanical work that 
may produce LV dysfunction (106). In summary, several mechanisms may lead to cardiac dysfunction 
in patients treated with anti-VEGF therapy: cKit inhibition, altered activation of MAP with 
consequent alteration of energy production and mitochondrial function, PDGFR inhibition, and 
inhibition of signaling favoring cell survival, as well as angiogenesis inhibition and induction of 
arterial hypertension. Importantly, hypertension is a main side effect of all three major anti-VEGF 
drugs (272). Mechanisms of arterial hypertension include both functional (inactivation of endothelial 
nitric oxide synthase and production of vasoconstrictors such as endothelin-1) and anatomic (capillary 
rarefaction) modifications, that lead to vasoconstriction and an increase in peripheral vascular 
resistance (272, 277, 353). The main mechanisms of capillary rarefaction are considered the loss of 
pericytes due to PDGFR inhibition, along with inhibition of angiogenesis by VEGFR inhibition (353). 
Moreover, renal dysfunction due to angiogenesis inhibition can play a role in inducing and 
maintaining arterial hypertension. All said, mechanisms of hypertension induced by antiangiogenic 
drugs have not been fully elucidated yet, and are still an unresolved issue. 
Bevacizumab produces severe hypertension that, at least in some circumstances, is not reversed by 
discontinuing the drug. Hypertension from anti-angiogenic agents has been suggestedto be a 
biomarker of anti-cancer drug efficacy, because some patients who developed hypertension were 
observed to survive longer than those who did not (122). It has been shown that in cases of metastatic 
colorectal cancer, 20% of patients showed grade 2-3 hypertension. A partial remission was observed 
in 75% of subjects with bevacizumab-induced hypertension, and in only 32% of those with no 
hypertension. Moreover, patients who showed grade 2-3 hypertension had significantly longer 
progression-free survival than non-hypertensive patients (342). Sunitinib can also cause hypertension, 
with an incidence ranging from 5% to 47% in different studies. Sunitinib was shown to induce 
hypertension (≥150/100 mmHg) in 47% of the subjects studied, with grade 3 hypertension seen in 
17%. High blood pressure was observed within the first 4 weeks of therapy (32, 270). 
Inhibition of VEGF signaling can also cause arterial and venous thrombosis. Arterial 
thromboembolic events (ATE) are mainly related to VEGF inhibition and consequent impairment of 
vascular homeostasis due to reduction of nitric oxide (NO) synthesis, endothelial dysfunction, and 
production of vasoactive mediators that favor plaque instability and thrombus formation (211). 
Bevacizumab causes ATE more frequently in patients contemporaneously treated with other 
chemotherapeutic agents, in older patients, and in those who have experienced previous thrombotic 
events (315). The real burden of venous thromboembolism related to bevacizumab is less clear (161). 
The pathogenesis of venous events is always related to impairment of vascular homeostasis due to 
VEGF inhibition and to production of proinflammatory cytokines that favor activation of the 
coagulation cascade (144). Sorafenib, pazopanib, and axitinib may also increase the risk of ATE. In 
a meta-analysis of  10,000 patients, the incidence of ATE was 1.7% in sorafenib-treated patients (49). 
Venous thrombotic events were reported in 3% of axitinib-treated patients, with ATE in 2% and 
transient ischemic attack in 1%. However, HF was observed in less than 1% of subjects treated with 
sorafenib and 3% of patients treated with pazopanib (324). Cardiac ischemia or myocardial infarction 
can also occur with sorafenib (3.8%), pazopanib (2%), and axitinib (<1%) (30). This is mainly related 
to inhibition of VEGF signaling, leading to endothelial dysfunction, vasoconstriction, and 
microvascular rarefaction. Moreover, a reduction in VEGF levels creates an imbalance between cell 
survival and apoptosis. Endothelial cell apoptosis favors an exposure of sub-endothelial collagen and 
activation of the coagulation cascade, while reduced VEGF levels also interfere with the platelet-
mediated fibrinolytic cascade (211). Finally, patients treated with sorafenib, pazopanib, and 
vandetanib can present an electrocardiogram (ECG) with QT interval prolongation, which 
predisposes to an enhanced risk of ventricular arrhythmias (194, 214). In particular, sorafenib can 
frequently induce QT prolongation (40.5%), thus greatly increasing the risk of ventricular 
arrhythmias (30). Vandetanib has also been related to a moderate risk of QT prolongation (16%), and 
more rarely life-threatening arrhythmias; in addition, it is associated with enhanced risk of arterial 
hypertension (24%) and HF (21%) (434). In patients treated with pazopanib, the risk of QT 
prolongation and torsade de pointes, a dangerous polymorphic ventricular tachycardia leading to 
sudden cardiac death, is less than 2% (303). 
In patients receiving drugs potentially interfering with QT duration, electrocardiographic monitoring 
of QT interval and periodic control of electrolytes are recommended. A reduction 
in the drug’s dose can be warranted, but rarely discontinuation. Particular attention should be 
paid to patients with personal or familial history of QT prolongation or those who are under 
concomitant medication that can influence QT interval. For further details on the approaches 
to reduce cardiovascular toxicity, see Sections 10 and 11. 
5. Tyrosine kinase inhibitors (TKIs) and anti-BCR-abl agents 
Chronic myeloid leukemia (CML) is a cancer of the white blood cells resulting from the 
clonal expansion of a transformed multipotent hematopoietic stem cell. It is characterized by a 
reciprocal translocation between the long arms of two chromosomes, namely chromosomes 9 
and 22. This translocation produces a shortened chromosome 22, the so-called Philadelphia 
chromosome. The consequence of such translocation is the production of the BCR-ABL1 
fusion gene on chromosome 22, and the reciprocal ABL1-BCR gene on chromosome 9. While 
the latter does not have any functional role in CML, the BCR-ABL1 fusion gene is necessary 
for CML pathogenesis. While the ABL1 tyrosine kinase is a master-regulator of the cell cycle 
regulation, the BCR-ABL1 fusion gene generates a constitutively active tyrosine kinase that 
leads to uncontrolled proliferation (332). 
Targeting the BCR-ABL1 fusion gene has revolutionized the management of CML, turning a 
fatal disease into a chronic disorder that in most cases is compatible with a normal lifespan 
(339). Based upon the data from the IRIS study, which documented a dramatic improvement 
in survival, imatinib was the first targeted drug approved for the therapy of CML (285). 
However, because of the development of a point mutation in the BCR-ABL1 fusion gene, a 
considerable number of patients may acquire resistance to imatinib (10). Second-generation 
TKIs - dasatinib, nilotinib, and bosutinib - have been shown to be effective in imatinibresistant 
patients, and more rapid in achieving a deep molecular response (57, 182, 383). 
Ponatinib, a third-generation TKI specifically designed to overcome resistance caused by a 
T315I mutation in BCR-ABL1 kinase, has exhibited high clinical efficacy in patients with 
multi-TKI-resistant CML (56). At their debut in the clinical arena, all five drugs appeared 
cardiologically safe; however, subsequent information indicated that they may exert adverse 
CV side effects which may affect prognosis and quality of life and must be taken into account 
when selecting treatment agents (266). All these drugs demonstrate significant off-target 
bindings and off-target effects, which may contribute to both toxicities and therapeutic control 
of the myeloproliferative disorder (124, 383). 
Imatinib was originally developed as a PDGFR inhibitor. It is a first-generation TKI that 
binds to the tyrosine kinase ABL while the protein is in the closed conformation and is 
inactive. It also inhibits other TKs, including VEGFR members and KIT family kinases (124). 
Imatinib adverse events: A 5-year follow-up study on patients with newly diagnosed CML 
treated with imatinib showed an excellent CV safety record for the drug (285). However, 
Kerkela et al. reported clinical data from 10 patients with normal ventricular function who 
developed severe cardiac dysfunction and New York Heart Association (NYHA) Class 3-4 HF 
after imatinib treatment, and demonstrated that mice treated with imatinib develop a severe 
form of LV contractile dysfunction (185). The publication by Kerkela et al. prompted many 
hematologists who had used imatinib to treat multiple patients to review their clinical 
database; the rates of CTX found were extremely low (16, 113, 138, 329). Further clinical 
studies then confirmed the excellent CV risk profile of imatinib (54, 60, 64, 80, 90, 148). 
Mechanisms of imatinib-induced adverse events: Several studies investigated the mechanisms 
responsible for cardiac toxicity, and found that imatinib-induced ABL inhibition leads to 
alterations in the endoplasmic reticulum (ER) stress response by activating the IRE1 kinase 
arm of the response. IRE1 activates apoptosis signal-regulating kinase 1 (ASK1) and c-Jun Nterminal 
kinase (JNK), which in turn causes inhibition of antiapoptotic Bcl-2 (B-cell leukemia/lymphoma) and 
cytochrome c release from mitochondria, thus leading to 
mitochondrial function impairment and cell death (43, 44). The inhibition of Abl kinase by 
imatinib is also responsible for PRKR-like endoplasmic reticulum kinase (PERK) activation, 
which results in impaired protein import in the mitochondrial matrix, inducing mitochondrial 
death pathways (409). 
Other than the potential proapoptotic effect on cardiomyocytes, imatinib has been shown to 
exert a number of cardiologically relevant effects. First, it causes fluid retention and edema 
that may contribute to a mistaken diagnosis of HF. This is probably due to imatinib’s 
inhibition of PDGFR (356). Paradoxically, imatinib treatment can also protect against brain 
and lung edema during stroke and lung injury, respectively (39, 374). It has been 
demonstrated that in human endothelial cells pre-treated with a variety of barrier-disruptive 
agents, imatinib reduces endothelial barrier dysfunction via inhibition of the abl-related gene 
(7, 47). Imatinib also has favorable effects on glucose control by improving both beta cell 
function and peripheral insulin sensitivity (101, 130). Imatinib improves hemodynamics and 
reverses vascular remodeling and cor pulmonale in pulmonary arterial hypertension by PDGF 
inhibition (343). Finally, imatinib was found to attenuate myocardial remodeling and improve 
LV diastolic dysfunction in spontaneously hypertensive rats by affecting the PDGRF pathway 
without the blood pressure-lowering effect (170). 
Nilotinib is a structural analog of imatinib, which binds and potentially inhibits PDGFR and 
KIT family kinases, but not kinases of the SRC group (124). It is approved for the therapy of 
subjects with newly diagnosed Ph+ CML in any phase. Nilotinib is also approved for CML 
patients resistant to or intolerant of previous therapies, including imatinib. 
Nilotinib adverese events: Early in the development of Nilotinib there was evidence of QT 
prolongation, leading to a warning to perform serial ECGs, prevent and correct electrolyte 
abnormalities, and avoid concomitant drugs potentially responsible of QT interval 
prolongation (182). However, subsequent trials found no alarming signals of QT-related 
ventricular arrhythmias (266). Clinical trials, as well as studies analyzing real-life settings, 
found that nilotinib exacerbates the glycometabolic and lipid profile (26, 166, 167, 266, 313, 
317). Over the past 5 years, several clinical trials, retrospective studies, meta-analyses, and 
postmarketing surveillance studies have shown that nilotinib-treated patients are at increased 
risk of CV events, especially those related to peripheral artery disease (2, 54, 64, 80, 118, 148, 
190, 209, 266, 403). Oddly, these vascular adverse events were not reported during the first 
clinical studies. 
Mechanisms of nilotinib-induced adverse events: Recent studies have documented a number 
of nilotinib-induced effects on endothelium, platelets, and coagulation, which, together with 
the metabolic effects, enhance the risk of vascular adverse events (4, 22). 
As for myocardial toxicity, clinical studies have shown that nilotinib does not cause 
ventricular dysfunction. This finding concurs with experimental data showing that nilotinib 
and imatinib produce little or no damage to cardiomyocytes, in comparison with dasatinib, 
bosutinib, and ponatinib (137). 
Dasatinib is a second-generation TKI, and more potent than imatinib. Unlike imatinib and 
nilotinib, dasatinib binds to TKs, both in their active and inactive conformational state. It is 
classified as a dual Abl/Src inhibitor, although it inhibits a broad spectrum of receptor kinases, 
including c-Kit and PDGFR (124). 
Dasatinib is approved as a frontline therapy of Ph+ CML patients in the chronic phase, and for 
salvage treatment of Ph+ CML or Ph+ acute lymphoblastic leukemia (ALL) patients who are 
intolerant of or resistant to other TKIs. 
Dasatinib adverse events: For years, the CV safety profile of dasatinib was considered similar 
to that of imatinib, with the exception of pleural effusion, which has been observed since the 
first use of the drug (383). Clinical studies with a long follow-up period found that pleural 
effusion occurs in one of every three patients, and that half of pleural events occur within the 
first 2 years of therapy. Pleural effusion requiring drug discontinuation occurs in less than 
10% of the cases (351). 
Pulmonary arterial hypertension (PAH) is a rare but serious complication of dasatinib 
treatment. A transient significant increase of pulmonary arterial pressure detected by 
echocardiography was observed for the first time in 2017 among patients with pleural 
effusion (312). Subsequently, other reports emerged of PAH not associated with pleural 
effusion (263). 
In clinical studies, PAH has been observed in 5% of subjects on dasatinib as a frontline 
therapy for 5 years and in 2.4% of patients treated with dasatinib for 7 years, who were 
resistant to or intolerant of other treatments (351). A recent assessment of all causes of 
dasatinib-related PAH confirmed by catheterization (41 patients) showed that a unique feature 
of dasatinib-induced PAH is different complete or partial reversibility upon drug 
discontinuation (352). However, the French PH Registry that identified nine cases of 
dasatinib-associated PAH reported that most patients did not experience complete recovery, 
and recorded two cases of cardiac death following dasatinib withdrawal (263). 
 
Analysis of the FDA database designed to support postmarketing surveillance found that PAH 
was associated with dasatinib and not with other TKIs, and often occurred in patients with CV 
risk factors or a medical history of cardiopulmonary events (54). 
Mechanisms of dasatinib-induced adverse events: Pleural effusion is considered the result of 
PDGFR inhibition, particularly of the PDGFR-β isoform, of which dasatinib is the most 
potent inhibitor; however, other mechanisms have been suggested (184). Due to the high 
frequency of lymphocytes in pleural fluid and tissue and the association with skin rash or 
history of autoimmunity, an autoimunne mechanism has been hypothesized (297). It has been 
suggested that an immune-mediated mechanism underlying the occurrence of pleural effusion 
could help to promote tumor regression. Patients who develop lymphocytosis and increased 
levels of specific lymphocyte subsets in association with pleural effusion have a higher major 
molecular response (MMR) rate and better progression-free and overall survival than patients 
who do not (89). 
The underlining molecular mechanism responsible for PAH is still poorly understood. Since 
dasatinib is a potent pan-Src inhibitor, it has been suggested that Src inhibition is pivotal in 
the development of PAH (264). The evidence that CML patients treated with dasatinib may 
display high circulating levels of E-selectin, intercellular adhesion molecule (ICAM), and 
vascular cell adhesion molecule (VCAM), and the observation that cultured pulmonary 
endothelial cells administered with dasatinib display an increased mitochondrial ROS 
production and apoptosis, support the notion that dasatinib-induced PAH is caused by 
endothelial dysfunction (127). 
Because vascular events have been described in patients treated with other TKIs, recent 
clinical trials have evaluated the incidence of coronary, cerebral, and peripheral thrombotic 
events in dasatinib-treated patients; a slightly higher risk was found, compared with imatinib. 
However, a recent meta-analysis showed that the use of dasatinib is associated with a 
significant increase in the risk of CV events. In a population-based cohort study, the incidence 
of myocardial infarction was 2.4 higher in patients treated with dasatinib than in those treated 
with imatinib. 
Bosutinib is a second-generation, dual Src/Abl TKI, lacking significant PDGFR or c-KIT 
binding properties (124). Bosutinib is currently approved only for patients with Ph1 chronic 
phase CML who were resistant to or intolerant of previous TKI therapy. 
Bosutinib adverse events: Studies that evaluated bosutinib enrolled patients newly diagnosed 
with CML, or patients resistant to or intolerant of other TKIs; these studies documented a low 
incidence of cardiac and vascular events (31, 55, 57, 58). Similarly to other TKIs, the 
incidence of adverse events was higher in second- or later-line treatment compared with firstline 
treatment. HF and coronary or peripheral artery disease-related events were rare, 
suggesting that the cardiotoxic profile of bosutinib differs from that of other second- or 
thirdgeneration 
TKIs. Most events occurred within the first year of therapy, and very few patients 
discontinued treatment because of these events, which were mostly managed with 
concomitant medications (55). 
It should be noted that in a first-line setting, the overall incidence of events and dose 
reduction or interruption is similar for imatinib and bosutinib, even though pericardial 
disorders occurred more often in bosutinib-treated patients than in those treated with imatinib. 
Ponatinib, a third-generation BCR-ABL TKI, was originally developed for the inhibition of 
pan-resistant ABL TK, and is clinically effective in imatinib-, nilotinib-, and dasatinibresistant 
CML. Ponatinib targets BCR-ABL in its inactive conformation and inhibits T315I 
and other BCR-ABL mutants. It also targets a broad spectrum of TK receptors, including 
EGFR, PDGFR, VEGFR, SRC kinase, c-KIT, FLT3, and RET (124). 
Ponatinib adverse events: Ponatinib was tested in Ph+ patients with refractory CML or ALL 
enrolled in phase I (65 patients) and in phase II (449 patients) of the PACE trial. Both studies 
documented a high efficacy of the drug, accompanied by an increased risk of arterial thrombotic 
events (56, 59). For these reasons, ponatinib was approved with a warning of the risk of 
serious vascular events. Findings from these studies provided the rationale to perform a phase 
III study (EPIC) to test the hypothesis that ponatinib may lead to a deep molecular response in 
patients newly diagnosed with CML, and to assess its safety in patients with no previous exposure 
to other TKIs (226). The extended follow-up periods of the phase I and II studies documented 
that cardiac, cerebral, and peripheral thrombotic events continued to occur; this finding 
determined the early termination of the phase III study and led ARIAD Pharmaceuticals 
and the FDA to withdraw ponatinib from the market in October 2013. In January 2014, after a 
reassessment of the benefit/risk ratio of ponatinib, the FDA allowed its reintroduction into the 
market, with a recommendation to take appropriate measures to mitigate adverse effects in patients. 
The mechanisms of ponatinib CV toxicity are still poorly understood. Diagnostic and 
pharmacological measures aimed at reducing the CV risk were not included in the protocols 
of the phase I-III trials. The implementation of these preventive measures may help to improve 
the therapeutic index of ponatinib in the clinical setting (27). For further details on the approaches to 
reduce TKIs-induced CTX, please refer to Sections 10 and 11. 
 
6. Taxanes 
Adverse effects: Although the potential of taxanes to induce cardiac dysfunction has been 
likely overestimated in the past, they deserve a brief note. The most commonly used taxanes 
are docetaxel and paclitaxel, which are still used in breast, non-small cell lung and ovarian 
cancers. Among adverse effects of these drugs, a high incidence of arrhythmias has been 
observed, including asymptomatic sinus bradycardia (330), which usually is not a major 
problem for patients. A large range of conduction blocks and cardiac ischemia have been also 
observed in a few patients participating in trials (330). Ventricular arrhythmias are far less 
common: only 0.26% of patients experienced ventricular tachycardia, and ventricular 
fibrillation, and many of them were also co-treated with cisplatin (245, 330) In a clinical trial 
(EORTC 24971/TAX 323 Study Group) patients treated with docetaxel, displayed a 1.7% 
incidence of cardiac ischemia (411). In about 3500 patients treated with paclitaxel followed 
by the Cancer Therapy Evaluation Program’s Adverse Drug Reaction database, the overall 
incidence of severe (grade 4 and 5) cardiac events was less than 0.3% (12). These severe 
events were observed up to 2 weeks after the beginning of paclitaxel treatment. Of note, many 
of these subjects had important cardiovascular risk factors, including coronary disease and 
hypertension. 
Mechanisms of adverse effects: Taxanes exerts anticancer effects acting as anti-microtubule 
agents and fostering polymerization of tubulin. In this way, these agents induce microtubule 
dysfunction and alter cell division. Moreover, they may affect histamine release (330). These 
taxane-induced effects may perturb cardiac function. Brady-arrhythmias may be due to 
stimulation of histamine H1 and H2 receptors. The latter receptors may increase the possibility of 
reentry of depolarization, which is at the basis of ventricular ectopy (245, 330). Ischemia 
and increased myocardial oxygen demands render the heart more susceptible to arrhythmias. 
Of note, paclitaxel in combination with anthracyclines increases the incidence of CTX, which 
appears at lower cumulative doses with respect to anthracyclines alone (120). In particular, 
plasma levels of doxorubicin and the formation of the toxic metabolite doxorubicinol in 
myocytes can be enhanced by taxanes. 
Ways to reduce cardiovascular toxicity: Cardiotoxic symptoms are frequently resolved upon 
discontinuation of taxanes. Since histamine is considered as a relevant player in taxane CTX, 
treatment with corticosteroids and antihistamines may reduce the incidence of clinically 
significant arrhythmias (245, 330). 
7. Cancer immunotherapy 
All components of the innate and adaptive immune system are important in the recognition 
and elimination of tumor cells (immune surveillance) (133). These immune components 
recognize specific neo-antigens expressed by tumor cells. However, the production of 
immunosuppressive cytokines/chemokines, the presence of immunosuppressive cells, or the 
expression of inhibitory checkpoints within the tumor microenvironment, allow the tumor 
cells to escape immune surveillance (296). 
Immune Checkpoint Inhibitors: Tumors exploit immune checkpoints to evade antitumor 
immunity. The success of cancer immunotherapy over the past decades has revolutionized the 
management of a wide array of malignancies. At the forefront of immunotherapy are immune 
checkpoint blockers, which have seen unprecedented success in cancer treatments because of 
their broad bioactivity across many tumor types. The two most prominent to date are the 
targeting of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and the interaction 
between the proteins programmed cell death 1 (PD-1) and programmed death-ligand 1 (PDL1). 
CTLA-4: It has structural homology to the co-stimulatory molecule CD28, and can also bind 
B7 molecules on antigen-presenting cells (APCs) with higher affinity than CD28. CTLA-4 is 
a competitive antagonist of the CD28-B7 interaction in that it blocks co-stimulation at the T 
cell-APC interaction, thus suppressing activation of its cell response (200) (Fig. 6). Ipilimumab 
and Tremelimumab are monoclonal antibodies for clinical use against CTLA-4 (117, 
354, 355, 431). 
PD-1/PD-L1 Pathway: PD-1 is a checkpoint receptor that, by binding with its ligands (either 
PD-L1 or PD-L2), inhibits T effector functions by dampening signaling downstream of the T 
cell receptor (TCR) (397). Therefore, the expression of PD-L1 in the tumor microenvironment 
protects cancer cells from immune-mediated destruction. Several monoclonal 
antibodies against the PD-1/PD-L1 axis have been developed and/or approved as anti-cancer 
agents (396, 397). 
PD-1, like CTLA-4, is expressed in activated cells, and its activation downregulates signaling 
mediated on antigen recognition by the TCR (354). PD-1 has two ligands, PD-L1 and PD-L2. 
PD-L1 can be expressed in many cell types, including tumor cells, immune cells, epithelial 
cells, and endothelial cells (354). PD-L2 is predominantly expressed in APCs. Pembrolizumab 
and Nivolumab are PD-1-blocking monoclonal antibodies approved for treating different 
types of cancers. Atezolizumab is a PD-L1 targeted monoclonal antibody recently approved 
for treatment of certain tumors (354). Other inhibitory molecules (e.g. LAG3, OX40, 
TIM3, TIGIT) are being assessed for their potential utility as immunotherapeutic targets (15, 
211, 279, 399). 
Combination of checkpoint inhibitors: CTLA-4 or PD-1/PD-L1 blockade as a monotherapy 
has shown impressive tumor regression in some patients with different solid and hematological 
cancers (95, 225, 241); however, the overall long-term survival rate should be improved 
(304). Ongoing clinical trials combine different checkpoint inhibitors. In addition, some clinical 
trials combine checkpoint inhibitors with angiogenesis inhibitors (i.e. bevacizumab), epidermal 
growth factor receptor (EGFR), TKIs or BRAF inhibitors, and chemotherapy or radiation 
therapy (396). Checkpoint inhibitors and immune-related adverse events: Checkpoint inhibitors can 
cause a 
novel spectrum of adverse events called immune-related adverse events (IRAEs) (254, 420), 
because they can induce autoimmune manifestations (75, 202). The most common IRAEs following 
treatment with CTLA-4 inhibitors include rash, diarrhea, colitis, hepatotoxicity, and 
endocrinopathies (115, 149). Immune-mediated CTX produced by these compounds has generally 
been observed in individual cases with variable presentations, comprising pericarditis 
and myocarditis (117, 141, 414, 431). The largest case series to date describing CTX following 
treatment with checkpoint inhibitors reported seven cases (141). 
Monoclonal antibodies targeting PD-1 (such as pembrolizumab, nivolumab, and pidilizumab) 
or PD-L1 (atezolizumab, durvalumab) have shown a favorable toxicity profile in several trials 
(82). However, occasional reports of myocarditis after nivolumab (151) or pembrolizumab 
(207) treatment have been reported. 
Although so far, there have been few case reports on cardiac adverse effects in patients treated 
with checkpoint inhibitors, several notes of caution should be considered. First, experimental 
data in PD-1-deficient mice are associated with dilated cardiomyopathy and sudden death by 
congestive HF (280, 288). In addition, PD-1 protects against inflammation in T cell-mediated 
myocarditis (385). Finally, PD-1 deficiency leads to the development of fatal myocarditis in 
mice genetically predisposed to autoimmunity (418). The latter observation is particularly 
important because patients with underlying autoimmune disorders have always been excluded 
from clinical trials with checkpoint inhibitors. Therefore, the real-life risk of cardiac adverse 
events in patients with autoimmune disorders treated with checkpoint inhibitors is so far unknown. 
Checkpoint inhibitors have only recently been introduced, and there are limited data on lateonset 
IRAEs after several years of initiating treatment. Careful follow-up of cardiac adverse 
events in long-term treated patients is warranted. Finally, and importantly, treatment with 
checkpoint inhibitors or sequential therapy with different checkpoint inhibitors, in association 
with chemotherapy or radiation therapy, is on the rise. Therefore, combination or sequential 




Fluoropyrimidines, such as 5-fluorouracil (5-FU), capecitabine, and gemcitabine, are used in 
the therapies of solid tumors such as gastrointestinal, breast, head, neck, and pancreatic cancer. 
5-FU reaches higher levels in cancer cells than in systemic circulation when administered 
intravenously. One 5-FU pro-drug is capecitabine, which is converted into its active form after 
oral administration (11, 188, 191, 253, 278, 302). 
Adverse effects: Although well-tolerated, both capecitabine and its main compound can induce 
CTX. The onset of capecitabine CTX is generally rapid. It usually occurs within 4 days 
from the start of the first cycle of chemotherapy (174, 175). Prospective and retrospective 
studies have shown that previous events of cardiac ischemia are the strongest risk factors for 
fluoropyrimidine-induced CTX (195, 309, 310). ECG abnormalities have been found in patients 
treated with a 24-hour 5-FU infusion in combination with capecitabine. Palpitations and 
chest pain are the most common clinical manifestations, accompanied by new-onset ECG alterations, 
such as ST segment deviation, sinus tachycardia, QT prolongation, and signs of 
myocardial ischemia and acute coronary syndromes. Less frequent are arterial hypertension, 
ventricular arrhythmias, LV dysfunction, HF, and cardiogenic shock. Cardiac arrest and sudden 
death are very rare events, and account for less than 1% of clinical manifestations (5, 198, 
309, 408). 
The incidence of CTX produced by 5-FU varies between 0-35%, with a mortality rate ranging 
between 2.2% and 13.3%, depending on the dose, cardiac comorbidities, and route of administration 
(198, 309, 310). Larger trials and meta-analyses on breast and colorectal cancer patients, 
however, have reported an incidence of symptomatic CTX of 1.2-4.3% during treatment (205, 407). 
A recent study found silent ischemia due to cardiac stress test in 6-7% of 5- 
FU-treated patients (216). Unfortunately, patients without overt CV risk factors are often 
treated as outpatients. As a result, symptomatic and asymptomatic cardiac events remain undiagnosed 
because of inadequate cardiac monitoring. This can lead to a discrepancy between 
observed and actual CTX, in terms of both symptomatic and asymptomatic patients. 
Mechanism of adverse effects: Although 5-FU has a brief half-life, active metabolites are retained 
in all tissues, including cardiac and cancer tissues, resulting in a prolonged exposure of 
cells to the drug (198, 215, 261). Thymidine phosphorylase, the pivotal enzyme involved in 
the conversion of capecitabine to 5-FU, is highly expressed in both atherosclerotic plaques 
and cancer tissues, explaining the higher prevalence of capecitabine-induced CTX in subjects 
with coronary artery disease. Nevetheless, the pathophysiological mechanisms underlying 
CTX from antimetabolite drugs remain poorly understood. Several mechanisms have been 
proposed (Fig. 7): i) Reduction in synthesis of nitric oxide (NO), with consequent coronary 
spasms and endothelium-independent vasoconstriction via the protein kinase pathway (52, 
296, 357); ii) increased intracellular ROS/RNS, with consequent oxidative stress and cardiomyocyte 
apoptosis (205); iii) increased endothelial thrombogenicity, with consequent induction 
of acute coronary syndromes (180); iiii) interference with DNA and RNA growth by substituting 
for the normal building blocks of RNA and DNA. 
The existence of a synergy between capecitabine and other anti-cancer drugs has also been 
suggested. Several studies have shown that CTX is more frequent in subjects administered 
with a combined therapy of capecitabine and either taxanes or lapatinib than in patients treated 
with capecitabine alone (105, 174, 175, 278). Studies in rabbits have shown that a single high dose 
of capecitabine caused hemorrhagic infarction 
of the ventricle walls, proximal spasms of the coronary arteries, and death within a 
few hours from intravenous injection. In contrast, repeated lower doses produced LV hypertrophy, 
concentric fibrous thickening of the coronary intima and foci of necrotic myocardial 
cells (398). Due to the importance of redox stress in antimetabolites-induced CTX, please refer 
to Sections 10 and 11 for ways to reduce this toxicity. 
 
9. Proteasome inhibitors 
Proteasome inhibitors are relatively novel anti-cancer therapies, particularly useful in the 
therapy of multiple myeloma and other hematologic conditions (amyloidosis, non-Hodgkin 
lymphoma). The first proteasome inhibitor approved for the treatment of cancer was bortezomib; 
second-generation drugs include carfilzomib, ixazomib, delanzomib, oprozomib, and 
marizomib (79, 201, 276). 
Adverse effects: Experimental data suggest that chronic (over 12 weeks) proteasome inhibition 
is associated with systolic dysfunction and increased atherosclerosis (143, 284). A metaanalysis 
conducted by Xiao and colleagues reported that the incidence of CTX in subjects 
treated with bortezomib varied with tumor type and treatment regimen, in the range 2.3% to 
3.8%, with a mortality rate of 3.0% (427). 
Treatment with proteasome inhibitors may be associated with hypertension, HF, myocardial 
infarction, and cardiac arrest, especially if such therapies are associated with concomitant use 
of doxorubicin, lenalidomide, and steroids, or in patients with a history of cardiac events (17, 
136, 151, 373, 423, 424). The incidence of HF in subjects receiving bortezomib is relatively 
low (up to 4%) compared with carfilzomib (up to 25%), a more potent and irreversible proteasomal 
inhibitor; patients treated with higher doses (≥36 mg/m2) of carfilzomib have a 
higher risk of cardiac toxicity (65, 328, 331). 
Mechanisms of adverse effects: Proteasome inhibitors are compounds that block the activity 
of proteasomes, protein complexes that play a key role in degrading dysfunctional or unneeded 
proteins; these cellular complexes that break down proteins are particularly important for the 
functional maintenance of cardiomyocytes. Therefore, cardiac dysfunction may be expected 
if the function of these complexes is impaired. 
Many mechanisms of chemotherapy-induced cardiotoxicity still remain to be clarified. It has 
been suggested (284) that bortezomib alters the function of cardiomyocytes through the impairment 
of' mitochondrial energetics. The cardiomyocytes are contractile cells with a very 
high demand for ATP and may be particularly sensitive to agents which disrupt mitochondrial 
activity, such as proteasome inhibitor bortezomib. Furthermore, a reduced synthesis of ATP 
could trigger the capillary tunneling, as revealed by histopathological examination of heart 
sections of rats treated with bortezomib (284). Chronic uptake inhibitor of the proteasome is 
associated with increased oxidative stress at the level of the intima of the epicardial coronary 
arteries, resulting in thickening of the vessel wall, which can trigger premature atherosclerosis 
(143). 
The addition of other chemotherapeutic agents such as ANT with proteasome inhibitors improves 
the effectiveness of antineoplastic therapy, however this combination of drugs can 
cause cardiotoxicity. Spur et al (368) have analyzed the function of the proteasome in primary 
cardiomyocytes treated with doxorubicin in the presence of proteasome inhibitors. Interestingly, 
the authors concluded that, opposite to carfilzomib, which targets both the β5 standard 
proteasome and the LMP7 immunoproteasome subunit, immunoproteasome-specific inhibitors 
with known anti-tumor capabilities for specific cancer cells, such as multiple myeloma, 
may be advantageous to reduce the mortality of cardiomyocytes, when there is a combination 
therapy, and therefore may be envisioned as a way to reduce cardiovascular toxicity, when 
compared to traditional proteasome inhibitors. Ways to reduce cardiovascular toxicity: The initial 
step in CV management of subjects treated 
with proteasome inhibitors is to assess their baseline risk for CTX, by taking a clinical history 
and conducting an examination. More frequent surveillance may be warranted for subjects 
with higher baseline clinical risk or abnormal cardiac baseline function. 
CTX induced by proteasome inhibitors may be reversible in some patients with prompt cessation 
of these therapies and initiation of traditional HF treatments (123). Angiotensinconverting 
enzyme inhibitors (ACE-Is) or angiotensin II receptor blockers (ARBs) in combination 
with β blockers are recommended in patients with symptomatic HF similar to the general 
HF population and in asymptomatic cardiac dysfunction, to prevent further cardiac dysfunction 
or the development of symptomatic HF in patients at high risk (432). 
Single-center experiences have shown a decrease in the occurrence of cardiac events when infusion 
time of carfilzomib was settled to 30 minutes and a cardioprotective activity of dexrazoxane 
(17, 136). 
In some cases, re-administration of carfilzomib with dose modification is possible. Long-term 
surveillance should be considered for patients who developed CTX during these therapies and 
for those in whom cardioprotective treatments have been started, to confirm recovery or to detect 
irreversible cardiac dysfunction. 
 
10. The importance of mechanisms such as oxidative and nitrosative stress in cardiovascular 
toxicity: An overview 
As reported above, the cardiotoxic mechanisms of several anticancer agents involve an 
unbalanced generation of ROS and RNS, leading to the so-called oxidative/nitrosative stress. 
ROS/RNS imbalance may derive from increased production or the inactivation of endogenous 
antioxidant enzymes by antineoplastic drugs, overwhelming the body’s defenses. Moreover, 
antioxidant resources (especially catalase) are lower in the cardiac tissue compared with other 
organs (e.g. the liver), making the heart more vulnerable to ROS/RNS injury (257,258). 
Low physiological levels of ROS/RNS regulate many CV physiological functions (Fig. 8). 
For instance, H2O2 produced by mitochondria is considered an endothelium-derived 
hyperpolarizing factor and metabolic vasodilator of the coronary circulation (293). 
High levels of ROS/RNS, overwhelming cellular antioxidant defense systems, may damage 
biomolecules and dysregulate cellular signaling pathways in the CV system. In particular, 
ROS/RNS can lead to membrane lipid peroxidation with subsequent membrane damage. 
ROS/RNS can also lead to DNA damage, and may trigger apoptotic cell death (Fig. 9). 
Cascade effects would include vacuolization and cardiomyocyte replacement by fibrous 
tissue, leading to irreversible damage (204, 219, 248-250, 333, 353, 376, 434). 
In the CV system, ROS are produced by many mechanisms and enzymes. Among the main 
ROS producers, there are xanthine oxidases and NAD(P)H oxidases (NOXs), as well as 
uncoupled nitric oxide synthases (NOSs), peroxisomes and mitochondrial complexes; ROS 
production may vary considerably among these enzymes (293, 323, 394). All these ROS 
producers are affected by multiple anti-cancer drugs (412). The heart is rich in mitochondria, which 
occupy 36-40% of the myocyte volume and produce 
approximately 90% of the cellular energy. Hence, derangements of mitochondrial function 
could be particularly critical in cardiomyocytes (293, 294, 394). Cardiomyocyte complexes of 
the mitochondrial respiratory chain, especially complexes I and III, are the main source of 
superoxide anions (O2 
.−). A common mechanism of cell death (necrosis and/or apoptosis) 
involves the opening of the nonselective mPTP, located between the mitochondrial 
membranes. The opening of mPTPs is facilitated by high ROS levels in the presence of Ca2+ 
overload and cyclophilin D activation. This pore opening allows the free passage of low 
molecular weight solutes (<1.5 kD), including cytochrome c, into the cytosol, where they can 
activate the apoptotic process. Moreover, a vicious cycle of ROS-induced ROS release 
(RIRR) takes place, leading to massive ROS production. If the mPTPs remain open, the 
mitochondria swell and expand owing to osmotic pressure, and ROS undermine membrane 
structure via lipid peroxidation; thus these processes disrupt the mitochondrial membrane and 
favor mitochondria rupture and cell death (293, 294). 
Another ROS source strongly affected by antiblastic agents is represented by the NAD(P)H 
oxidase system, which comprises several isoforms, namely NOXs 1-5 and dual oxidases 
DUOX1/2. Myocardial NOX2, normally quiescent, produces O2 .– when activated, whereas 
NOX4, which is constitutively active, generates hydrogen peroxide (H2O2). Moreover, 
superoxide dismutases (SODs) may convert O2 .– to H2O2, which is a relatively stable 
molecule. In specific compartments, including mitochondria, H2O2 may be converted to  oxygen and 
water by catalase and by glutathione peroxidase (GPx). However, especially in 
the presence of iron complexes, these ROS may be converted to the more toxic hydroxyl 
radical (OH.–) by several processes within and outside mitochondria (293, 294, 298, 394). 
Also peroxisomes, cytoplasmic organelles specialized for carrying out oxidative reactions, 
may have a pivotal role in ROS production/regulation in cardiomyocytes. A variety of 
substrates are broken down by oxidative reactions in peroxisomes, including amino acids, uric 
acid, and fatty acids. In cardiomyocytes, fatty acid metabolism is very active and peroxisomes 
are critical for processing long carbon chain fatty acids. Although the role of these organelles 
in CTX is poorly studied, it is likely they have a key role in determining the fate of 
cardiomyocytes exposed to cardiotoxic agents (433). 
Nitric oxide (NO) is a redox species with both oxidant and antioxidant properties (293, 394) 
NO responses in tumor biology display a biphasic nature (323). NO is produced by 
biologically important enzymes, namely the three isoforms of NOS: the endothelial (eNOS or 
NOS3) and neuronal (nNOS or NOS1) NOSs, which are constitutively expressed in specific 
compartments of the cardiomyocytes, and the inducible NOS2 (iNOS), which is induced by 
pro-inflammatory mediators or by ischemic episodes (293, 394). NO can also be produced by 
other reactions in biological systems, which are collectively termed ‘non-NOS’ processes 
(293, 298, 323). Of note, ROS can react with NO to generate RNS, thus amplifying the 
production of oxidant compounds, and NOS itself when uncoupled may produce ROS (102, 
293, 298, 394). S-nitrosylation (SNO) is the covalent attachment of a NO moiety to a protein thiol 
group. As recently reviewed (293, 298), SNO is a redox-dependent modification that 
often exerts an antioxidant effect, shielding critical cysteine residues from oxidation and 
affecting protein function (Fig. 10). 
The toxic effect produced by many anti-cancer drugs is derived from an altered production of 
ROS/RNS by different cellular components and enzymes (102, 246, 247, 367). For instance, 
several drugs alter the activity of redox enzymes within and outside the mitochondria, 
including an impairment of NOSs, respiratory complexes, the Krebs cycle, oxidative 
phosphorylation, and β-oxidation. This impairment results in oxidative/nitrosative stress, a 
reduction in antioxidant capacity, and induction of cell death (3, 102, 246, 247, 367). Also 
iNOS upregulation may be involved in carcinogenesis (140). 
In the following paragraphs, we analyze the specificity of redox alterations induced by 
different chemotherapeutics; particular attention is paid to those exerted by ANTs, which for 
their adverse side effects and for historic reasons are the cardiotoxic agents most studied, and 
which are still in use for the therapy of solid and hematological malignancies. 
The generation of ROS, with a consequent rise in oxidative stress, has been considered a key 
event in ANT-induced CTX. ROS are then effectors of membrane lipid peroxidation, 
vacuolization, irreversible damage, and myocyte replacement by fibrous tissue (204, 219, 
248-250, 333, 353, 376, 434). 
ANTs trigger the generation of ROS, affecting the activity of mitochondrial enzyme 
complexes, NOSs, NAD(P)H oxidases, catalase, and GPx, and leading to oxidative stress and cell 
injury. ANTs can be quickly converted to unstable metabolites (such as doxorubicinsemiquinone), 
which in turn can react with O2, producing H2O2 and O.− 
2. In addition, ANTs 
chelate the free intracellular iron, forming iron-doxorubicin complexes. These can react with 
O2, leading to the generation of ROS. Finally, ANTs are able to directly interfere with the 
main iron-transporting and -binding proteins (114, 250). The Ardehali lab (163) has reported 
that doxorubicin impairs the expression of ABCB8, a mitochondrial iron exporter, with 
consequent iron accumulation within these organelles and subsequent ROS generation. 
Accordingly, overexpression of ABCB8 in isolated cardiomyocytes in vitro, and in the hearts 
of transgenic mice in vivo, has been proposed as the mechanism protecting from ANT-induced 
CTX, lowering levels of mitochondrial iron and redox stress. Hearts from patients who 
developed cardiac dysfunction following ANT treatment exhibit much higher mitochondrial 
iron levels than normal hearts or hearts affected by different types of dysfunction (163). Such 
findings support the hypothesis that mitochondrial iron accumulation and oxidative stress play 
a key role in ANT-induced CTX. Experimental studies have shown that the NRG-1/ErbB axis 
can modulate and counteract the increase in oxidative stress induced by doxorubicin (262, 
390), suggesting that CTX from ErbB2 blockade can also involve a dysregulation of redox 
homeostasis (250). 
A portion of cardiac damage induced by ANTs results from their high affinity for cardiolipin, 
a mitochondrial membrane phospholipid involved in apoptotic pathways. The interaction of 
ANTs with cardiolipin leads to a high concentration of the drug in these organelles. Once 
accumulated in the mitochondria, the drug may exert adverse effects such as ROS generation, 
inhibition of oxidative phosphorylation, and mitochondrial DNA damage. During the initial phases, 
ROS can lead to peroxidation of cardiolipin, which may induce the release of 
mitochondrial apoptogenic factors, including cytochrome c, which in turn can trigger more 
cardiolipin peroxidation. This leads to a cycle that exacerbates ANT-induced injury. Of note, 
NO may inhibit the peroxidase activity of cytochrome c on the cardiolipin complex and can 
thereby block cardiolipin oxidation. Thus, it may be argued that site-specific and appropriate 
amounts of NO, which exerts antioxidant properties, may counteract the toxic effects of ANTs 
(121, 308, 413). 
Although much of ROS generation appears to take place in the mitochondria, soluble 
oxidoreductases of the cytoplasm, such as the xanthine oxidase and coenzyme of the 
NAD(P)H-dependent cytochrome P450 reductases of the ER, may be targeted by ANTs in 
altering redox equilibrium. For example, doxorubicin deoxyaglycone may be obtained by a 
reduction process occurring in the ER. Deoxyaglycone may then accumulate in the 
membranes, where it can alter the function of complex I (NADH dehydrogenase) in 
membrane mitochondria, or the NOXs, in the plasma membrane (389). Both an excessive 
production of NO by ANT-induced iNOS and a reduced level of NO, resulting either from the 
quenching of NO by the superoxide anion to form peroxynitrite (ONOO−) or from uncoupled 
NOS, have been described as responsible for some of the damage induced by these drugs 
(103). More studies are required to elucidate the role of such enzymes and of other lesscharacterized 
intracellular signaling molecules in ANT-induced CTX. However, these data 
confirm how the oxidative reactions at the basis of ANT-induced cardiac dysfunction are 
involved in most kinds of HF, suggesting that timely innovative pharmacological strategies that 
interfere with specific molecules involved in heart dysfunction, such as p53, may 
represent a potential common approach in the fight against HF (250). 
Oxidative stress may also play a role in CTX derived from TKIs: It has been observed that 
direct infusion of sunitinib in different experimental preparations provoked a dose-dependent 
cardiodepressant effect, accompanied by decreased levels of intracellular Ca2+, with a 
concomitant rise in ROS generation (314). 
In addition, 5-FU can also induce oxidative stress in cardiomyocytes and endothelial cells. In 
particular, the toxic effect exerted by this drug on the vascular endothelium determines eNOS 
dysregulation, endothelin 1 upregulation, and the activation of protein kinase C. These effects 
may lead to endothelium-dependent and -independent vasoconstriction, and subsequently to 
coronary spasms (5, 365). 
10.1 Drugs with antioxidant properties 
The cardiotoxic mechanisms involving oxidative stress provide the rationale for using 
drugswith antioxidant properties (29, 34, 73, 219, 224, 242, 350, 366, 379, 381), (Fig. 11). 
The iron-chelating drug dexrazoxane has been identified as the most promising cardioprotective 
strategy in the past years and, up to now, is the only cardioprotective drug approved by 
the FDA for ANT-induced CTX. Dexrazoxane is a pro-drug that, once it enters the cardiomyocyte 
and rapidly turned into its active form, counteracts the formation of ANT-iron complexes 
and the subsequent formation of ROS (358) (Table 2). Its efficacy has been extensively 
tested in multiple randomized trials and two pooled analyses (350, 379), and confirmed in different 
subsets of cancer patients (222, 381). 
It is likely that dexrazoxane possesses unique pharmacodynamic protective mechanisms, because 
no other iron chelator has shown any cardioprotective effects (358). At the molecular 
level, dexrazoxane has been shown to modify the Top2β configuration, preventing its interface 
with ANTs, thereby impeding the realization of the Top2-DNA cleavage complexes 
(213, 229). However, dexrazoxane has been underused in recent years, despite strong evidence 
of its cardioprotection (367). While CTX mitigation induced by new-generation β 
blockers could be due more to their antioxidant properties than to their β-adrenergic receptorblocking 
action (243, 366, 430), it appears that the cardioprotective effect of iron chelators 
does not stem from their antioxidant properties, but rather from their ability to affect iron regulatory 
proteins and to reduce iron accumulation (42, 114). Interestingly, close derivatives of 
dexrazoxane lacking Top2β were found not to be protective in relevant chronic ANT CTX 
models (178, 242) which also suggest Top2β importance in the cardioprotective mechanism. 
These observations indicate that anthracycline-mediated damage relies on complicated alterations 
of the intracellular metabolic pathways or Top2β interaction. Moreover, recent preliminary 
data from Stěrba and coworkers suggest that cardioprotective effects of dexrazoxane 
against chronic anthracycline cardiotoxicity are due to its interaction with Top2-β, rather than 
to its metal chelating metabolite (213, 372). Nevertheless, the discordant results underline the 
need for further investigation to ascertain the exact biological interaction of anti-cancer drugs 
with the cellular redox balance. 
10.1.1 β blockers: Anti-adrenergic and antioxidant drugs 
β blockers are a cornerstone therapy in patients with reduced LVEF to prevent symptomatic 
HF (311), and many researchers encourage their use in asymptomatic ANT-related LV dysfunction 
(62, 367). The rationale for β blocker use in ANT-induced CTX rests mostly on 
experimental indications of their cardioprotective effects. Moreover, a recent retrospective 
survey in breast cancer patients administered with ANTs and trastuzumab showed that 
patients who received β blockers during their treatment exhibited a significantly lower 
incidence of HF, supporting the hypothesis that blockage of the β-adrenergic receptor (β-AR) 
may be cardioprotective during antiblastic therapies (347) (Table 2; Fig. 11). 
Long-dated evidence shows β-AR signaling alterations in ANT-induced cardiomyopathy-like 
features and in other forms of dilated cardiomyopathies (108) and several animal models have 
shown a specific positive effect of β-AR blockage in mitigating oxidative stress, reducing 
myocardial calcium overload (14, 275), and preserving epidermal growth factor signaling (87, 
189). 
The cardioprotective role of the new-generation β blockers, like carvedilol and nebivolol, has 
also been evaluated. In one study, carvedilol, a non-selective β- and α1-AR antagonist with 
strong antioxidant properties, was compared to atenolol, a β blocker without antioxidant 
properties, and showed greater protection against ANT-induced cardiomyopathy; the protective 
effect of carvedilol, therefore, seems to be related more to its antioxidant properties than 
to the β-AR blocking action (243). Carvedilol can prevent ANT-induced ROS release, cardiomyocyte 
apoptosis (366), and mitochondrial respiration alterations, along with calcium overloading 
(337). A small randomized placebo-controlled clinical trial on the cardioprotective effect 
of prophylactic-use carvedilol in patients undergoing ANT chemotherapy showed a reduced 
incidence of LV systolic and diastolic dysfunction in the carvedilol group (181). However, 
strong clinical evidence of the cardioprotective effect of carvedilol is still lacking.  
Nebivolol is a cardio-selective β blocker with limited vasodilating properties related to its interaction 
with the L-arginine/NO pathway. In an experimental model of ANT-induced CTX, 
treatment with nebivolol, and to a lesser extent with carvedilol, led to an improvement in LV 
function associated with increased NO levels and a significant reduction in oxidative stress 
(71, 393, 394). A small randomized placebo-controlled study on the prophylactic use of 
nebivolol in patients undergoing ANT chemotherapy showed, at the 6-month follow-up, a reduced 
incidence of LV dilatation and systolic dysfunction in the nebivolol group compared 
with the placebo group (183). In addition, by enhancing prosurvival ERK signaling after 
ErbB2 inhibition (87), β blockers can also prevent trastuzumab-related CTX (Table 3); β 
blockers are now studied in a series of clinical trials such as the MANTICORE 101 and the 
SAFE trials (33). As said, recent data from the PRADA trial indicated that the β1 blocker 
metoprolol was not cardioprotective (128), thus supporting the use of unbiased β1 and β2 
blockers (382). 
In summary, different β blockers are not similarly effective in treating CTX. The molecular 
and cellular mechanisms by which β blockers may confer cardioprotection are not completely 
clear. To date, a cardioprotective treatment with β blockers should still demonstrate its efficacy 
in large clinical trials. Additionally, in clinical practice, use of β blockers is hampered by 
their side effects in an already-fragile patient, suggesting their use only in patients with a high 
CTX risk. 
10.1.2 The redox role of renin-angiotensin-aldosterone system (RAAS) antagonists: 
angiotensin-converting-enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers 
(ARBs) Many studies have found a key role for RAAS in modulating ANT-induced CTX (13). ACEIs 
and ARBs have already been shown to exert positive effects in reducing the progression of 
LV dysfunction and preventing HF in asymptomatic high-risk patients (311). 
The rationale for using RAAS blockade drugs in this setting is based on the high risk of developing 
myocardial dysfunction after ANT treatment. Experimental studies have shown the 
efficacy of ACE-Is in countering ANT-induced CTX, both acute high dose (1) and single low 
dose (24). The underlying mechanisms of their positive effect against ANT-related CTX contribute 
to neutralizing ROS damage, reducing interstitial fibrosis, avoiding intracellular calcium 
overload, and improving mitochondrial respiration and cardiomyocyte metabolism (1, 24) 
(Table 2; Fig. 11). Indeed, activation of the AT1R produces direct adverse cardiovascular effects 
by stimulating NADPH oxidase, which is involved in the genesis of oxidative stress, and 
initiating MAPK, related to cell growth, inflammation, hypertrophy, and apoptosis (25). 
Experimental animal models of acute and chronic ANT-induced cardiomyopathy showed a 
cardioprotective role for prophylactic administration of enalapril, captopril, and lisinopril (1). 
In a study of 115 patients treated with ANTs, enalapril was shown to significantly reduce the 
incidence of LV dysfunction in comparison with a placebo (36). 
Candesartan has been shown to treat experimental cardiotoxicity already induced by anthracyclines 
(364); while pre and post treatment with telmisartan protected against acute doxorubicin- 
induced cardiotoxicity in rats (164). Telmisartan is the only ARB modulating peroxisome 
proliferator-activated receptor-γ (PPAR-γ), and, therefore, affecting the bioavailability 
of NO, and inhibiting inflammatory molecules such as interleukin 6 (IL-6) and tumor necrosis 
factor (TNF) (428). In a small prospective study, telmisartan was shown to mitigate subclinical 
cardiotoxic effects (changes in strain rate) of epirubicin, with IL-6 and ROS increasing 
significantly in the placebo arm but not in the telmisartan arm (34). Telmisartan could reverse 
acute (early) EPI-induced myocardial dysfunction and maintain a normal systolic function up 
to the 18-month follow-up (73, 74). IL-6 and ROS increased significantly in the placebo arm 
but did not change in the telmisartan arm. In another study, valsartan showed a cardioprotective 
effect on acute cardiotoxicity in patients treated with high doses of ANTs (274). 
Recent clinical trials have shown that a combination of ACE-Is and β blockers is beneficial in 
treating ANT-induced CTX (23). Many other ongoing clinical trials are evaluating the role of 
ACE-Is and ARBs as cardiopreventive agents that may act by decreasing angiotensin-induced 
blockade of the neuregulin 1/ErbB pathway. 
Finally, a recent meta-analysis showed that the prophylactic administration of ACE-Is and 
ARBs in patients on ANT therapy was associated with a reduced relative risk of developing 
CTX compared with patients on a placebo (180). To date, however, a cardioprotective treatment 
with ACE-Is or ARBs still requires a demonstration of efficacy in large clinical trials. 
Additionally, in patients with anti-angiogenic drug-induced hypertension, nondihydropyridine 
calcium channel blockers are not indicated, because of the pharmacokinetic 
interaction of sorafenib and sunitinib with CYP3A4 (33, 236). Thus, acknowledging the other 
mechanisms responsible for sunitinib-induced CTX, i.e., disrupted mitochondrial function and 
impaired myocyte energy homeostasis, ACE-Is and β blockers (85, 106) could form an effective 
cardioprotective strategy (Table 3). Unfortunately, no clinical study to date has shown a 
role for these drugs in preventing sunitinib-induced CTX (33). 
 
10.2 Novel strategies in cardioprotection against ANT-induced CTX 
Several CV drugs have tested as potentially effective in counteracting ANT-induced CTX, 
and particularly statins, ranolazine, and phosphodiesterase-5 inhibitors. 
Lovastatin and fluvastatin, HMG-CoA reductase inhibitors, showed a cardioprotective effect 
in experimental studies (159, 320). Of notice, these data derive from acute, subacute experimental 
cardiotoxicity studies and cell-based studies performed on proliferating H9c2 cell line, 
not cardiomyocytes. Therefore, effects of anthracyclines in this setting deserve caution since 
these drugs possess strong antiproliferative action besides cardiotoxic effects. The effects of 
the statins on the Top2b have not been directly demonstrated in the studies, just indirectly 
suggested to be Top2b-related. Beside these caveats, left ventricular systolic dysfunction induced 
by doxorubicin was not affected by lovastatin (142). Only small clinical studies have 
evaluated the effects of statins in patients treated with ANTs (48, 348), reporting only minor 
positive results. Unfortunately, the study from the Marwick group (348) was a retrospective 
observational analysis, and even Chotenimitkhun and collaborators (48) do not appear to have 
conducted a standard controlled randomized trial. Therefore, larger studies are therefore required 
to confirm these findings. 
Late INa inhibition with ranolazine has been proposed as a cardioprotective strategy in several 
experimental models of cardiac dysfunction (316, 391, 394). Ranolazine was shown to preserve 
heart function in mice treated with ANTs by reducing oxidative stress. Inhibiting elevated 
[Na+]i levels with ranolazine would prevent calcium overload and the occurrence of oxidative 
damage by suppressing ROS generation, offering an advantage over conventional antioxidant 
strategies that counteract ROS after their production (196). The INTERACT study (259), designed to 
assess whether ranolazine could prevent ANT-induced diastolic dysfunction, 
indicated that ranolazine was a promising cardio-oncologic drug, but more convincing 
data are still required. 
Phosphodiesterase-5 inhibitors have also been tested as cardioprotective agents. Sildenafil 
demonstrated cardioprotective activity against ANT-induced LV dysfunction by opening 
mitochondrial 
KATP channels, preserving mitochondrial membrane potential and myofibrillar integrity, 
and preventing cardiomyocyte apoptosis (100). Tadalafil attenuated ANT-induced 
cardiomyopathy through NO-mediated increases in cGMP levels (177, 197). 
Finally, redox mechanisms have also been proposed for the ability of NRG-1 to limit 
antiblastic drugs-induced damage in adult rat cardiomyocytes (390). 
Another redox compound attracting the interest of researchers and cardio-oncologists is 
hydrogen sulfide (H2S), whose role in cancer is still poorly understood. The discoveries that 
ROS-induced inhibition of cystathionine gamma-lyase, a key enzyme in the synthesis of H2S, 
is involved in ANT-induced CTX in H9c2 cardiomyocytes, and that the administration of 
exogenous H2S can confer protection against this CTX, have suggested a new tool with 
antioxidant properties in therapeutic strategies against antineoplastic drugs-induced CTX (33, 
247, 295). Further research in appropriate animal models is required, as well as multi-centric 
randomized trials that compare the efficacy of these new compounds with that of already 
approved cardioprotective drugs. 
Experimental studies have shown that sunitinib inhibits AMPK activity, while restoration of 
this enzyme’s activity inhibits cell death (186). It has been speculated that promoting AMPK 
activity with metformin may reduce sunitinib-induced CTX. Although metformin can counterheart 
dysfunction in different experimental models of cardiac injury (53, 129) (Table 3), an in 
vitro study that focused on sunitinib-related CTX did not find any beneficial effect of metformin 
(33). As mentioned above, a recent study (98) demonstrated that TrkB, a tyrosine kinase 
receptor, and its endogenous ligand BDNF could directly modulate the cardiac excitation- 
contraction coupling, independently or in parallel with GPCR-mediated signaling, supporting 
the concept that inhibition of the tyrosine kinase receptor with antineoplastic drugs 
can interfere with fundamental pathways, damaging cardiac contractility (106). At the same 
time, this study highlights BDNF as an alternative potential therapeutic strategy for HF. 
10.3 Non-pharmacologic strategies 
Apart from pharmacologic interventions, we should also consider that nutritional 
supplementation and exercise training may have important antioxidant properties (8, 139, 
192, 345, 346, 359, 369). 
Dietary supplementation of antioxidants showed to be able to alleviate doxorubicin 
cardiotoxicity in animal models (8, 426). Althoug there is still scant evidence in both quality 
and sample size, suggesting that some antioxidant supplementations may lower ANT-induced 
CTX (109). Non-pharmacologic strategies for countering ANT-induced CTX include lifestyle 
interventions and exercise “prehabilitation,” a type of preventive exercise rehabilitation. It has 
been speculated that aerobic exercise can decrease ROS generation, inhibiting pro-apoptotic 
signaling, restoring proper calcium cycling, and stimulating the AMPK pathway, thus 
improving myocardial energetics (345) (Table 3). In addition, exercise can have a positive 
impact on CV risk factors, such as hypertension, high cholesterol and lipids, overweight and obesity, 
and high blood glucose or diabetes (192). In cancer survivors, a short period of mixed 
aerobic and resistance exercise builds tolerance and flexibility in physical activity (369). 
Although several studies have shown a role for aerobic exercise in countering ANT- (343) 
and trastuzumab- (139) related CTX, additional work is needed to better characterize the effects 
of training on antineoplastic drug-induced CTX (346). 
 
10.4 Biomarkers of oxidative/nitrosative CTX 
Since the importance of ROS/RNS production as early mediators of chemotherapy-related 
CTX has been ascertained, we should identify useful circulating biomarkers of 
oxidative/nitrosative CTX. Biomarkers with redox significance include the metabolomic 
identification of acetate and succinate (8). A decrease in NAD(P)H:quinone oxidoreductase 1 
activity and an increase in ROS generation by NAD(P)H oxidases have been considered early 
biomarkers of ANT-induced CTX (283). A significant variation in IL-6, IL-6R, and ROS has 
been observed together with a change in the enzymatic activity of GPx, which was correlated 
with an early variation in longitudinal systolic function in patients after the administration of 
epirubicin (73, 74). 
Other potential CTX markers with redox importance under investigation in cardiology are 
high-sensitivity C-reactive protein, heart-type fatty acid-binding protein (H-FABP), glycogen 
phosphorylase BB (GPBB), and circulating microRNAs, especially microRNA-146a (miR- 
146a). These are considered new potential markers for the diagnosis and risk stratification of 
acute coronary syndromes, and may be helpful in early detection of anti-cancer CTX however, the 
clinical data available in the chemotherapy-induced CTX scenario remain 
insufficient (131, 152-155, 371, 419). For discussion on other biomarkes see sub-section 11.4. 
 
1. Early detection, monitoring, and management of heart and vascular toxicities 
11.1 Cardioncology: an expanding science for an expanding problem 
Assessing CTX from antineoplastic drugs is essential. Screening for CTX at a pre-clinical 
stage is essential when investigating the effects of TKIs. Many of these drugs cause an 
increased risk of arrhythmia, thus most of the pre-clinical work focuses on hERG (K+ 
channel). A major limitation of in vitro work is that primary myocyte cultures of animal or 
human hearts dedifferentiate and die after a short while. Hence, assays based on stem cells 
and on the use of engineered heart tissue may better reflect in vivo settings. Such experimental 
studies could integrate assessment of several effects, including those on membrane action 
potential, calcium cycling, and myofilament function, as well as those on gene expression and 
cell survival (69, 88, 236, 376). 
In clinical practice, most of the methods used to assess heart function are often inaccurate, 
and may also mislead physicians to stop potentially lifesaving therapies. Of note, patients 
with advanced cancer may already exhibit potential confounder symptoms mimicking anticancer 
drugs’ side effects. Moreover, complications such as myocardial ischemia, arterial 
hypertension, and dysrhythmias are readily recognized, but identifying mild LV dysfunction 
(especially at a subclinical stage) can be more challenging (376). In this context, a prompt and 
sensitive monitoring of CV function plays a pivotal role. 
In addition, the time point when CTX can become clinically overt varies substantially. Several 
antineoplastic drugs, (i.e. ANTs) can induce progressive cardiac remodeling and late 
cardiomyopathy, while others (i.e. trastuzumab) can produce transient LV dysfunction without 
known long-term consequences (376, 432). Furthermore, the inability to exactly predict the 
long-term consequences of tumors, leads to false diagnosis of CV complications. Owing to all 
these concerns, cardioncology, a new branch of CV sciences recently developed, with the aim 
to prevent, identify and treat CV complications of cancer therapy, optimizing clinical status 
for cardiac patients who need potentially cardiotoxic treatment, facilitate in any way cancer 
therapy in patients with CV complications and surveille for late side effect in cancer 
survivors. 
11.2 Diagnostic tools for CTX detection 
The most common clinical diagnostic tools for screening and detection of CTX are 
biomarkers and cardiac imaging including echocardiography, multiple-gated acquisition 
(MUGA) scan and CMR (Table 4). Nevertheless, an ECG is recommended for all subjects 
before and during therapies, particularly for detecting arrhythmias and QT interval 
prolongation. Moreover, subjects on pyrimidine analogs should be monitored closely for 
cardiac ischemia by regular ECGs, and chemotherapeutic treatments should be withheld if 
ischemia is observed (432). 
11.3 LVEF and emerging modalities for assessing myocardial damage: some claryfing points 
LVEF is the most frequently used parameter for assessing myocardial function, and 
echocardiography and MUGA scans are largely employed in clinical practice for this purpose 
(40, 41, 62, 171, 206, 234, 299, 307, 376, 432, 438). An LVEF decrease (>10%) to a value 
<50% identifies patients with CTX in both imaging modalities (307, 432). Compared with 
echocardiography, MUGA provides the advantage of a high reproducibility, but is hampered 
by significant disadvantages, such as cumulative radiation exposure and no data on other 
cardiac structures (299, 432). However, the choice of modalities for an early detection and 
monitoring of CTX depends upon local expertise and availability being careful to use the 
same imaging modality with the best reproducibility for continued screening throughout the 
treatment period (432). Imaging techniques that provide additional relevant clinical 
information (e.g. right ventricular function, pulmonary pressures, valvular function, 
pericardial evaluation) and high-quality radiation-free imaging are preferred (307, 432). 
Confirming LVEF decrease by repeated cardiac imaging (preferably by echocardiography) 2 
to 3 weeks following the baseline initial decrease in LVEF is strongly recommended, as well 
as categorizing LVEF reduction as asymptomatic or symptomatic, and repeating 
echocardiography measurements during follow-up (432). Repeated MUGA is not 
recommended as a first-line option, and should only be conducted if the radiation exposure is 
less than 5 mSv (432). 
On the other hand, echocardiographic measurements, though simple, non invasive and readily 
available, are often variable and of low sensitivity (290), because of the serious damage and 
myocyte loss leading to an observable reduction in LVEF (92, 416). On these grounds, novel 
indices of ventricular function are being introduced (37, 146, 150, 206, 386). Speckle tracking 
echocardiography has shown the highest sensitivity in detecting early alterations in LV 
function associated with future development of cardiomyopathy (134, 146, 306, 307, 395, 
438). In particular, a global longitudinal strain (GLS) >15% relative percentage reduction 
from baseline can identify patients at risk for CTX (97, 172, 307, 432). 
Other imaging modalities, such as CMR, appear very promising, although their availability is 
still limited (97, 238, 290, 299, 388, 415). CMR is the gold-standard technique for LVEF 
estimation and can identify myocardial edema, inflammation, capillary leak, and fibrosis, 
enabling an accurate diagnosis of early and late CTX (239, 388, 432). Other recent strategies 
include measuring uptake of iodine-124-metaiodobenzylguanidine (MIBG), a radiolabeled 
analog of norepinephrine, which is reduced after myocardial insults (145, 239, 415). In 
addition, antimyosin antibodies that detect myosin exposed after cardiac damage could be 
useful (235, 239, 401, 402), while the uptake of radiolabeled chemotherapeutics could be used 
as a predictor of CTX (18, 239, 301). 
11.4 Cardiac biomarkers. Troponins and natriuretic peptides can be correlated with findings 
from cardiac imaging for early detection of CTX (283, 292). Natriuretic peptide level elevations 
were demonstrated to predict the development of future CTX in patients with NHL and 
with breast cancer (99, 119). Persistent B-type natriuretic peptide (BNP) rises, after exposure 
to anthracyclines, were more predictive of following LV dysfunction than transient elevations 
(327, 335). However, the utility of NPs for predicting anticancer drugs-induced CTX is still 
controversial. Indeed, several studies did not confirm a prognostic value for BNP levels especially 
when this biomarker was used alone (66, 340, 378). It has been observed that troponins 
I and T can predict late ANT-induced CTX in children (223) and in adult patients undergoing 
high dose chemotherapy. Not only the increase, but also the pattern of the elevation and particularly 
a persistent increase after 1 month since treatment, added prognostic information. 
Conversely persistently negative TnI identified low risk patients who did not need a strict 
cardiological follow up (38). Patients with troponin increase may benefit from early cardioprotective 
treatment with ACE-Is (36). In patients treated with trastuzumab, especially after 
previous exposure to ANTs, troponin I elevation can identify those who will develop LV dysfunction 
and who will not recover in spite of treatments for HF (37). High-sensitivity troponin 
I is more sensitive in the evaluation of subclinical depletion of cardiac physiologic reserve 
and a new elevation of this marker predicted subsequent LV dysfunction in patients receiving 
conventional dose of ANTs and/or trastuzumab (203). The combination of high- sensitivity 
troponin with GLS predicted the risk to develop future cardiotoxicity with increased sensitivity 
(93%) and negative predictive value (91%) compared with the evaluation of a single parameter 
in patients with breast cancer (340). Therefore “cardiac biomarkers plus cardiac imaging" 
should be encouraged to early detect CTX. There is still scant data supporting the use 
of biomarkers to predict future cardiac dysfunction due to immune and targeted cancer therapies. 
Few data indicated an increase of troponin in subjects administered with sunitinib and 
sorafenib for metastatic renal cell carcinoma, who developed ventricular function impairment 
(344). Several other biomarkers have been studied or are under investigation to stratify the 
risk of cardiotoxicity. Myeloperoxidase (MPO), an index of oxidative stress, measured after 
anthracycline administration, seems to correlate with subsequent development of CTX (203). 
Fatty acid bing protein (FABP) and Glycogen phosphorylase BB (GPBB) have also been proposed 
as novel biomarkers of chemotherapy mediated cardiac damage even more precocious 
of troponin and BNP (86, 152, 153). MicroRNAs have emerged as an attractive tool to detect 
myocardial injury. miR-146a may induce downregulation of ErbB4 and subsequent stimulation 
of apoptotic pathways. Preclinical studies have shown increased levels of miR-146a after 
doxorubicin administration (155). However more trials with long-term follow-up are needed 
to validate these data. 
The use of cardiac biomarkers in the prediction of cardiotoxicity has several advantages (accuracy, 
reproducibility, high-sensitivity, wide availability and relatively low cost), but also 
limitations, for example inter assay variations, insufficient evidence to establish specific cut 
offs for enzyme elevations in this setting, uncertainty in the timing of blood sampling (432). 
Standardization in the assessment of cardiac toxicity using biomarkers is needed and multicentre 
trials are strongly required before establishing more clear recommendation (376) Table 
5 summarizes main biomarkers evaluated for the detection of cardiac toxicity. 
11.5 Detection of vascular complications: old and new strategies 
Structural endothelial damage, endothelial dysfunction, acceleration of atherosclerosis, 
prothrombotic actions, and vascular inflammation are some of the underlying mechanisms of 
cancer therapy-related changes in vessel function. VEGF inhibitors, TKIs (such as nilotinib, 
ponatinib, dasanitib), cisplatin, 5-FU and ANTs can induce hypertension, ischemia and 
thromboembolism (TE) through their endotelial toxicity. Coronary artery disease, (CAD), 
stroke, peripheral artery disease (PAD), pulmonary arterial hypertension (PAH), 
arterial/venous TE disease and nephrotoxicity are the main cinical presentations of vascular 
damage by cancer therapy. In particular, nuclear cellular actions by ANTs may adversely 
modulate collagen turnover and vascular wall homeostasis, leading to acute damage 
(endothelial dysfunction, increase in smooth muscle tone) and chronic damage 
(atherosclerosis, increased collagen synthesis), and resulting in an impaired CV coupling (81, 
84, 273). Age and CV risk factors may influence the extent of cardiac dysfunction (Fig. 12). 
VEGF inhibitors increase vascular tone due to a decrease in NO production, increased 
peripheral resistance from endothelial damage (sloughing) and dysfunction, and capillary 
rarefaction (96). Cisplatin can induce myocardial ischemia through an increased procoagulant 
status. 
For an early detection of vascular complications, current reccomendations (432) simply 
suggest to monitor CV risk factors, assess patient functional status, measure blood pressure 
before cancer treatment and optimize anthypertensive therapy during treatment with a goal of 
< 140/90 mmHg (particularly in patients treated with VEGF inhibitors). Moreover, the 
identification of patients with pre-existing CAD in those undergoing 5-FU is of paramount 
importance since this drug substantially increases the risk of developing myocardial ischemia 
with a vasospam recognized mechanism. In addition, it should be considered that clinical 
factors (cancer-, treatment- and patient-related) could be related to enhanced risk of venous 
thromboembolism in subjects administered with TKIs. Nilotinib, ponatinib, and BCR-ABL 
TKIs used in treating CML are, instead, associated with PAD and stroke. The evaluation of 
PAD risk at baseline (risk factor assessment, clinical examination, ankle-brachial index 
measurement) is therefore recommended in these patients (432). Moreover, cerebrovascular 
ultrasound screening is indicated in subjects irradiated for head and neck cancer or 
lymphoma, especially beyond 5 years after irradiation (432). 
However, a common standard approach useful in clinical practice for and early detection of 
vascular complications such as atherosclerosis is missing, to date. 
The assessment of arterial stiffness, which early increases in atherosclerotic process, in order 
to provide vasculotoxic profiles of chemotherapeutic agents seems to be very proimising. 
These could be useful in the future in improving therapeutic strategies (84, 179, 273, 425). 
Drafts et al. found, by magnetic resonance imaging of the aorta, an early (approximately 3 
months) and abrupt increase of pulse wave velocity (PWV), a marker of arterial stiffness, 
which was dose-, age-, and CV risk factor-independent in patients treated with ANTs; 
furthermore, this increase was accompanied by a subclinical reduction in LVEF and strain 
(81). This is one of the first demostration of early atherosclerosis with associated impaired 
ventricular-arterial coupling in cancer survivals. More recently, a marked stiffening of large 
elastic arteries was demonstrated by applanation tonometry also in patients undergoing 
VEGF-inhibitors (265). Accordingly, ACE-Is should be preferred because of their antistiffening 
properties in the aorta in hypertensive patients treated with ANTs and VEGF 
inhibitors. 
11.6 Timing of clinical evaluation and follow-up: the importance of risk factors assessment 
To date, no algorithm has been established for evaluation and follow-up of patients before, 
during, and after cancer therapies. However, a strong collaboration between cardiologists and 
oncologists is required to monitor and treat oncology patients (3, 432). Of course, the cardiooncology 
team must be equipped appropriately to address the most common questions (i.e. 
CTX prediction, prevention strategies, high-risk patient monitoring, management strategies) 
with an evidence-based approach (410, 425). 
Long-term surveillance of cancer survivors with a potential for late-onset CV complications 
should involve cardio-oncology teams. According to recent clinical guidelines on cancer 
treatment and CV toxicity, the first step in cardioprotection should be the identification of 
subjects at higher risk; this depends on several factors: cumulative dose, body mass index 
(BMI)>30 (especially for anti-HER2 compounds), age (elderly and pediatric population 
treated with ANTs) (199, 376, 380), concomitant or previous radiation therapy, previous 
cardiotoxic cancer treatment, pre-existing conditions such as CVD, demographic and other 
CV risk factors, and lifestyle and genetic risk factors that may predispose patients to CTX at 
lower ANT doses (37, 50, 432). Although recent experimental studies from Moulin and 
collaborators (271) seem to suggest the opposite, female patients appear to be more 
susceptible to doxorubicin damage (222-224). 
Gender-specific pharmacokinetic differences or even a degree of protection conferred by 
androgens could be responsible for this phenomenon. It has been observed that testosterone 
can reduce ANT-induced damage in cardiac myocytes in vitro (6). 
11.7 Drug-specific timing for CTX monitoring and treatment 
The exact timing and frequency of imaging and/or biomarker sampling will depend on the 
specific antineoplastic therapy, total cumulative dose, treatment protocol and duration, and 
baseline CV risk (432). 
ANTs: Doxorubicin and epirubicin can induce acute CTX (including ECG changes, 
supraventricular and ventricular arrhythmias, or transient LV dysfunction), which is usually 
reversible, develops in <1% of patients immediately after infusion of ANTs; early or subacute 
cardiotoxic effects, occurring within the first year of treatment, and late effects with typically 
are those manifesting after a median of 7 years. Early or subacute CTX, the most frequent, 
requires a baseline evaluation and further assessment at the end of the treatment, particularly 
in presence of an enhanced risk for CTX, or with consecutive treatment with potentially 
cardiotoxic-targeted therapeutics. For higher dose anthracycline-containing regimens, and in 
subjects with high baseline risk, earlier evaluation of heart function after a cumulative total 
doxorubicin (or equivalent) of 240 mg/m2 should be considered (432). 
Anti ErbB2: Since patients receiving anti-ErbB2 therapeutics frequently receive also ANTs, a 
baseline evaluation is always recommended. Usually, cardiac assessment is performed every 3 
months during and once after completion of anti-ErbB2 therapies. An improvement in early 
detection of cardiac dysfunction with troponins and GLS measurements every 3 months 
during adjuvant trastuzumab treatment has been demonstrated. Troponin dosage with every 
cycle may be considered in patients with high baseline risk (variability in the timing of 
trastuzumab induced cardiac dysfunction) (432). 
VEGF-inhibitors: The best timing of surveillance strategies still needs to be clarified. There is 
high variability in the time of occurrence (early after treatment and delayed for several 
months). Currently it is reasonable to consider evaluations every 6 months initially until 
stability in values of LVEF is achieved. With high baseline risk, it is better to perform early 
clinical assessment in the first 2-4 weeks after starting targeted therapies. There is limited 
evidence to support any specific surveillance strategy. In addition, treatments with anti 
VEGF-inhibitors (236) pose a high risk (11-45%) of inducing new hypertension or 
destabilizing previously controlled hypertension, including severe hypertension in 2-20% of 
cases (255, 432). Monitoring blood pressure is therefore essential, and susceptible patients 
should preferably be treated with ACE-Is, ARBs, or β blockers instead, considering the 
beneficial role of these drugs in HF (236, 370, 376). 
With regards to therapeutic implications, beyond anthypertensive treatment, eventual standard 
HF therapy can be administered (62, 376, 392), and with good life expectancy, aggressive 
treatments with LV-assist-devices can also be considered (322, 376). To prevent and treat 
vascular complications, such as PAD, antiplatelet therapy is recommended (432). Significant 
stenosis (e.g. those of carotid arteries) may need stenting or surgery. Targeted therapy for 
PAH can be used temporarily or permanently. Management of QT prolongation is usually dependent 
on correction of the predisposing factors (e.g. concomitant electrolyte abnormalities, 
QT-prolonging drugs). Commonly, an individualized approach for the management of atrial 
fibrillation is needed, and decisions on rate or rhythm control should be patient-centred and 
symptom directed. Anticoagulation for venous TE prevention in patients with cancer should 
always be considered according to the patient’s bleeding risk and life expectancy (432). 
12. Conclusions and perspectives 
Antineoplastic therapies have led to a prolonged life expectancy for many patients, but CTX 
is a relatively common adverse effect of these therapies. Apart from direct myocardial toxicity 
of single drugs, cardiac dysfunction and HF may be exacerbated by drug-drug interactions, 
which are not only due to treatment with multiple anti-cancer drugs, but also to the disparate 
drugs necessary to mitigate symptoms. Even targeted therapies that were traditionally considered 
less toxic may exert CTX. Moreover, drugs used to prevent cardiovascular complications 
have raised some concern about cancer induction (68). Improving the quality of patient care 
in the CTX setting is, indeed, a complex issue. Despite several proposed strategies to reduce 
anticancer drugs-induced CTX, LV systolic dysfunction and HF still occur in cancer survivors. 
The scientific community has recognized the complexity of these toxicities, and is developing 
multidisciplinary strategies to prevent or minimize CTX and its long-term effects 
(425). Understanding the mechanisms by which anti-cancer treatments affect the heart is critical 
for implementing optimal drug design and proposing alternative therapies. Multidisciplinary 
teams should work to develop methods to reduce the influence of risk factors and to detect 
and treat potential CTX (3). Early detection requires awareness of chemotherapy-related 
cardiac dysfunction, as well as appropriate prevention, cardiac evaluation, and follow-up. 
These aspects are needed to protect individuals predisposed to CVD. Very often, many of the 
patients developing adverse CV events have preexisting known CVD or at least CV risk factors, 
for which they should receive appropriate treatment and adequate prevention counseling. 
Measures “that rest on common sense,” such as exercise, are recommended for all patients 
receiving potentially cardiotoxic therapy (367). These measures include the management of 
preexisting comorbidities and recommendations for a healthy lifestyle, and should be suggested 
both before and after initiating cancer therapy. In the absence of specific cardiac monitoring 
guidelines for potentially cardiotoxic agents, the evaluation and monitoring of LVEF 
must be considered. However, the prognostic value of serial measurements of LVEF during 
treatment to detect and monitor CTX remains controversial. Several biomarkers have been 
proposed, which ideally should be simple to measure, widely available, low-cost, and extensively 
used in treating other pathological conditions. For instance, troponin has been proposed 
for CTX monitoring, but its practical use has yet to be shown definitively (292, 376, 432). 
Hope for progress comes from the development of new promising technologies, including the 
omics sciences, immunotherapy, investigations of ROS-dependent pathways, and further 
work involving stem and progenitor cells (250) from both adult and embryonic sources, 
which so far have been investigated for their capacity to repair and regenerate CV tissues 
(233, 260). Since actively replicating cells are the main target of anti-cancer chemotherapy, 
stem and progenitor cells may be a targeted by drugs involved in the onset and development 
of chemotherapy-induced CTX (20, 260, 363). Specifically, cardiac-derived progenitor or 
stem cells (CPCs/CSCs) from the adult heart have recently attracted attention as a tool for 
studying chemotherapy-induced cardiomyopathy and HF (67, 72). CPCs/CSCs which may 
exist in specific architectural microenvironments known as “cardiac stem cell niches”, have 
very recently entered the clinical trial arena (233, 338). Various cell subtypes have been 
(magnetically) isolated on the basis of specific antibody binding, or pre-plating in fibronectincoated 
culture dishes (yielding cell aggregates known as cardiospheres), therefore producing 
c-kit+/lineage- cells, Isl1 cells (193, 208, 436) and cardiosphere-derived c-Kit+/Sca-1+ cells. 
These cells are proposed as adult, multipotent stem cells, capable of self-renewal in culture, 
and of differentiating into several cardiac lineages, such as endothelial cells, smooth muscle 
cells and cardiomyocytes. 
CPCs/CSCs can participate to cardiac regeneration (193, 208, 237, 252, 436) and cardioprotection 
by releasing paracrine factors such as insulin growth factor (IGF), granulocyte-colony 
stimulating factor (G-CSF), VEGF, and stem cell-derived factor (SDF)-1α (20, 260, 319, 
363), although to date there is little data documenting the extent and burden of this process in 
the adults. CPCs/CSCs differentiation may be also responsible of the late-onset ANT-induced 
CTX, which is an important issue in pediatric oncology (147, 158). CPCs/CSCs may be sensitive 
to interference from a wide range of anti-cancer drugs, resulting in accumulation of oxidative 
DNA damage, growth arrest, inhibition of CPCs/CSCs proliferation, cell senescence, 
expression of p53, telomere attrition, and cell necrosis and apoptosis (67, 72). In particular, 
anti-cancer chemotherapy may inhibit the expression of c-kit, resulting in impairment of 
CPCs/CSCs mobilization in the damaged area (107), and may impair several signaling pathways 
including Akt, VEGF, and Notch (251). 
Therefore, the idea that autologous CPCs/CSCs can be obtained before antineoplastic drug 
treatment and used in cancer patients sensitive to antineoplastic CTX, for management or prevention 
of HF, has been proposed (67, 289). Repopulating the damaged heart by boosting endogenous 
CPCs/CSCs may represent an alternative strategy by which these cells can contribute 
to myocardial protection, neovascularization, and the reduction of cardiac fibrosis after 
chemotherapy-induced CTX (76, 360). However, since the actual existence of CPCs/CSCs 
and their regenerative capacity have been questioned and are still controversial (with specific 
reference to the c-kit cells (375, 404-406), further studies are required to clarify several critical 
questions (e.g. the burden of endogenous cardiac regenerative process supported by 
CPCs/CSCs, identification of the molecular mechanisms by which protection, regeneration, 
and neovascularization may occur), before these approaches are introduced in clinical practice. 
Indeed, among stem cells, induced pluripotent stem cells (iPSCs) are of great interest for 
research and application in regenerative medicine, disease modeling, drug discovery and in 
the determination of drug toxicity (83). All these aspects need to be further investigated. 
Considering all these perspectives, animal studies which model risk factors for CVD and 
comorbidities are currently essential for adequate successive clinical translation. Basic and 
translational studies may help to identify novel and highly effective therapeutic strategies to 
prevent CTX induced by antincancer therapeutics. The main aim of these studies must be the 
early identification such cardiovascular alterations, thus preventing their CV side-effects, and 
the development of more personalized treatments. In this regard, the addition of genetic profiling 
to clinical risk factor assessment is expected to assist in identifying subjects at high risk 
of developing CTX in the future. There is an urgent need to close this gap in our knowledge 
in order to identify and establish optimal strategies of prevention and management that balance 
effectiveness of cancer therapy with long-term health (232, 425). This is a particularly 
delicate task, since redox signaling is involved in both mitogenic regulation and tumor suppression 
(156). Also, on one side, experimental data suggest that antioxidants may be effective 
in shielding the the cardiovascular system from toxicity, but on the other, clinical use of 
cardioprotective antioxidants is controversial because of the potential reduced cytotoxic efficacy 
against cancer. Further experimental and clinical studies, in particular well designed randomized 
clinical trials, are therefore needed to assess this important issue (412). 
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Figure 2. Simplified algorithm showing the factors related to anthracycline therapy or patient 





















Figure 3. ErbB receptor homodimerization or heterodimerization is induced by stressors, including 
anthracycline therapy, with consequent complex intracellular pathway activation. Cascade effects can 
be avoided by treatment with monoclonal antibodies and tyrosine kinase inhibitors (TKIs). See the 











Figure 4. Vascular endothelial growth factor receptor (VEGFR) activation triggers a complex 
intracellular pathway. Cascade effects can be avoided by treatment with anti-angiogenic drugs acting 


















Figure 5. Schematic illustration of how tyrosine kinase inhibitor (TKI) antagonists induce cardiac 
















Figure 6. A) Dying tumor cells release tumor neo-antigens that are taken up by antigenpresenting 
cells (APCs), which then present B7 co-stimulatory molecules to T cells. T cells recognize tumor 
neo-antigens on APCs and are activated. Activated T cells upregulate inhibitory checkpoints, such as 
CTLA-4 and PD-1, which block T cell activation and attack of tumor cells. B) Ipilimumab blocks 
CTLA-4, resulting in T cell activation and destruction of tumor cells. See the text for further 
explanation and acronyms. 
  
 
 
 
  
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
  
 
  
 
  
  
  
  
 
